

Basic Search

[Advanced Search](#) [Search Preferences](#)

angiogenesis biocompatible muscle delivery system

Search

☒ Journal sources ☒ Preferred Web sources ☒ Other Web sources ☐ Exact phrase

Searched for:: :All of the words:angiogenesis AND biocompatible AND muscle AND delivery AND system

Found:: :8 total | 0 journal results | 6 preferred web results | 2 other web results

Sort by:: :relevance | date

Save checked results


Email checked results

Export checked results

☐ 1. SYSTEM FOR TREATING ISCHEMIA

CAFFERATA, Robert, L. / C.R. Bard Inc., EUROPEAN PATENT, Jul 2001

...of smooth muscle. The therapeutic...catheter based **delivery system** for delivering...formed of a **biocompatible** material...formed of a **biocompatible** material...agent. The **biocompatible** material of the **delivery system** can include...


Full text available at patent office. For more in-depth searching go to  LexisNexis **similar results**

You
ang
bio
AN
We
que
anc
ess

☐ 2. SYSTEMS AND METHODS FOR TREATING ISCHEMIA

CAFFERATA, Robert, L. / C.R. BARD, INC., PATENT COOPERATION TREATY APPLICATION, Mar 2000

...further embodiment, the **biocompatible** material of the apparatus...comprising a body formed of a **biocompatible** material containing at...therapeutic agent. The **biocompatible** material of the **delivery system** can include a drug releasing...

Full text available at patent office. For more in-depth searching go to  LexisNexis **similar results**

Or
AI
F

☐ 3. No Title [PDF-242K]

Oct 2004

NEW YORK UNIVERSITY A private university in the public service OFFICE OF INDUSTRIAL LIAISON/ TECHNOLOGY TRANSFER TECHNOLOGIES AVAILABLE FOR LICENSING New York University 650 First Avenue, 6th Floor, New York, N.Y. 10016 PHONE (212) 263-8178 FAX (212) 263-8189 www.med.nyu.edu.

[http://www.med.nyu.edu/oil/assets/Book10_2004.pdf]

similar results

☐ 4. Supplement to the [PDF-2MB]





Jun 2005

Supplement to the AUSTRALIAN OFFICIAL JOURNAL OF PATENTS The Australian Official Journal of Patents (Supplement) is part of the Official Journal issued by the Commissioner of Patents for the purpose of the Patents Act 1990, the Trade Marks Act 1995 and the Designs Act 1906.

[<http://pericles.ipaustralia.gov.au/ols/epublish/conten...>]

similar results

5. HUMAN POLYNUCLEOTIDES AND POLYPEPTIDES ENCODED THEREBY

- ❑ **MISHRA, Vishnu, S. / SPYTEK, Kimberly, Ann / TAUPIER, Raymond, J., Jr. / VERNET, Corine, A., M. / COLMAN, Steven, D. / GORMAN, Linda / TCHERNEV, Velizar, T. / (...) / PADIGARU, Muralidhara, PATENT COOPERATION TREATY APPLICATION, Mar 2002**
 ...unique to the triad junction in skeletal **muscle** was identified as a novel member of the...MG29 is expressed abundantly in skeletal **muscle** and at lower levels in the kidney. Immunofluorescence...endoplasmic reticulum. systems in skeletal **muscle** and renal tubule cells. Physiological...
Full text available at patent office. For more in-depth searching go to  LexisNexis
[similar results](#)
- ❑ **6. BIOACTIVE COATING COMPOSITIONS AND METHODS**
ZAMORA, Paul, O. / OSAKI, Shigesasa / TSANG, Ray / BIOSURFACE ENGINEERING TECHNOLOGIES, INC., PATENT COOPERATION TREATY APPLICATION, Feb 2002
 ...fibroblasts, endothelial cells, smooth **muscle** cells, osteoblasts, and chondrocytes...cell attachment of fibroblasts, smooth **muscle** cell and endothelial cells. The fibroblasts...colony stimulating factor. Examples of **angiogenesis** inhibitors include platelet factor-4...
Full text available at patent office. For more in-depth searching go to  LexisNexis
[similar results](#)
- ❑ **7. ANGIOGENESIS - ASSOCIATED PROTEINS, AND NUCLEIC ACIDS ENCODING THE SAME**
RASTELLI, Luca, K. / GERRITSEN, Mary / GENENTECH, INC., PATENT COOPERATION TREATY APPLICATION, Sep 2001
ANGIOGENESIS ASSOCIATES PROTEINS, AND NUCLEIC ACIDS ENCODING THE SAME RELATED APPLICATIONS This application claims priority to U.S. provisional...delicate monolayer of remarkably plastic endothelial cells lining the luminal walls. Depending on location and function, smooth **muscle** and connective tissue may also be present. Not only do healthy cells depend on the blood resources transported by the circulatory...
Full text available at patent office. For more in-depth searching go to  LexisNexis
[similar results](#)
- ❑ **8. IMPROVEMENTS IN OR RELATING TO DIAGNOSTIC/THERAPEUTIC AGENTS**
KLAVENESS, Jo / RONGVED, Pål / I / HØ / GSET, Anders / TOLLESHAUG, Helge / CUTHBERTSON, Alan / (...) / GOGSTAD, Geir, PATENT COOPERATION TREATY APPLICATION, May 1998
 Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming...
Full text available at patent office. For more in-depth searching go to  LexisNexis
[similar results](#)

fast 

[Downloads](#) | [Subscribe to News Updates](#) | [User Feedback](#) | [Advertising Test Zone](#) | [Tell A Friend](#) | [Terms Of Service](#) | [Privacy Policy](#) | [Legal](#)

Powered by FAST © Elsevier 2005



Basic Search

[Advanced Search](#) [Search Preferences](#)

angiogenesis biocompatible muscle delivery system

Search

☒ Journal sources
 ☒ Preferred Web sources
 ☒ Other Web sources
 ☐ Exact phrase

Searched for:: :All of the words:angiogenesis AND biocompatible AND muscle AND delivery AND system

Found:: :8 total | 0 journal results | 6 preferred web results | 2 other web results

Sort by:: :relevance | date

Save checked results

Email checked results

Export checked results

☐ 1. SYSTEM FOR TREATING ISCHEMIA

CAFFERATA, Robert, L. / C.R. Bard Inc., EUROPEAN PATENT, Jul 2001

...of smooth muscle. The therapeutic...catheter based **delivery system** for delivering...formed of a **biocompatible** material...formed of a **biocompatible** material...agent. The **biocompatible** material of the **delivery system** can include...

Full text available at patent office. For more in-depth searching go to LexisNexis
[similar results](#)

☐ 2. SYSTEMS AND METHODS FOR TREATING ISCHEMIA

CAFFERATA, Robert, L. / C.R. BARD, INC., PATENT COOPERATION TREATY APPLICATION, Mar 2000

...further embodiment, the **biocompatible** material of the apparatus...comprising a body formed of a **biocompatible** material containing at...therapeutic agent. The **biocompatible** material of the **delivery system** can include a drug releasing...

Full text available at patent office. For more in-depth searching go to LexisNexis
[similar results](#)

☐ 3. No Title [PDF-242K]

Oct 2004

NEW YORK UNIVERSITY A private university in the public service OFFICE OF INDUSTRIAL LIAISON/ TECHNOLOGY TRANSFER TECHNOLOGIES AVAILABLE FOR LICENSING New York University 650 First Avenue, 6th Floor, New York, N.Y. 10016 PHONE (212) 263-8178 FAX (212) 263-8189 www.med.nyu.edu.

[http://www.med.nyu.edu/oil/assets/Book10_2004.pdf]

[similar results](#)

☐ 4. Supplement to the [PDF-2MB]

Jun 2005

Supplement to the AUSTRALIAN OFFICIAL JOURNAL OF PATENTS The Australian Official Journal of Patents (Supplement) is part of the Official Journal issued by the Commissioner of Patents for the purpose of the Patents Act 1990, the Trade Marks Act 1995 and the Designs Act 1906.





[<http://pericles.ipaustralia.gov.au/ols/epublish/conten...>]

[similar results](#)

5. HUMAN POLYNUCLEOTIDES AND POLYPEPTIDES ENCODED THEREBY

You
ang
bio
AN
We
que
anc
ess

Or
AI
f

- ☐ **MISHRA, Vishnu, S. / SPYTEK, Kimberly, Ann / TAUPIER, Raymond, J., Jr. / VERNET, Corine, A., M. / COLMAN, Steven, D. / GORMAN, Linda / TCHERNEV, Velizar, T. / (...) / PADIGARU, Muralidhara, PATENT COOPERATION TREATY APPLICATION, Mar 2002**
 ...unique to the triad junction in skeletal **muscle** was identified as a novel member of the...MG29 is expressed abundantly in skeletal **muscle** and at lower levels in the kidney. Immunofluorescence...endoplasmic reticulum. systems in skeletal **muscle** and renal tubule cells. Physiological...
Full text available at patent office. For more in-depth searching go to  [similar results](#)
- ☐ **6. BIOACTIVE COATING COMPOSITIONS AND METHODS**
ZAMORA, Paul, O. / OSAKI, Shigesasa / TSANG, Ray / BIOSURFACE ENGINEERING TECHNOLOGIES, INC., PATENT COOPERATION TREATY APPLICATION, Feb 2002
 ...fibroblasts, endothelial cells, smooth **muscle** cells, osteoblasts, and chondrocytes...cell attachment of fibroblasts, smooth **muscle** cell and endothelial cells. The fibroblasts...colony stimulating factor. Examples of **angiogenesis** inhibitors include platelet factor-4...
Full text available at patent office. For more in-depth searching go to  [similar results](#)
- ☐ **7. ANGIOGENESIS - ASSOCIATED PROTEINS, AND NUCLEIC ACIDS ENCODING THE SAME**
RASTELLI, Luca, K. / GERRITSEN, Mary / GENENTECH, INC., PATENT COOPERATION TREATY APPLICATION, Sep 2001
ANGIOGENESIS ASSOCIATES PROTEINS, AND NUCLEIC ACIDS ENCODING THE SAME RELATED APPLICATIONS This application claims priority to U.S. provisional...delicate monolayer of remarkably plastic endothelial cells lining the luminal walls. Depending on location and function, smooth **muscle** and connective tissue may also be present. Not only do healthy cells depend on the blood resources transported by the circulatory...
Full text available at patent office. For more in-depth searching go to  [similar results](#)
- ☐ **8. IMPROVEMENTS IN OR RELATING TO DIAGNOSTIC/THERAPEUTIC AGENTS**
KLAVENESS, Jo / RONGVED, Pål / I / HØ / GSET, Anders / TOLLESHAUG, Helge / CUTHBERTSON, Alan / (...) / GOGSTAD, Geir, PATENT COOPERATION TREATY APPLICATION, May 1998
 Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming...
Full text available at patent office. For more in-depth searching go to  [similar results](#)



[Downloads](#) | [Subscribe to News Updates](#) | [User Feedback](#) | [Advertising Test Zone](#) | [Tell A Friend](#) | [Terms Of Service](#) | [Privacy Policy](#) | [Legal](#)

Powered by FAST © Elsevier 2005

SCIRUS - ☐ Pop-up Blocker OFF ☐ Highlight

- [About Us](#) [Newsroom](#) [Advisory Board](#) [Submit Web Site](#) [Search Tips](#) [Contact Us](#)

Basic Search

[Advanced Search](#) [Search Preferences](#)

Angiogenesis muscle biocompatible catheter

☒ Journal sources ☒ Preferred Web sources ☒ Other Web sources ☐ Exact phrase

Searched for:: :All of the words: **Angiogenesis AND muscle AND biocompatible AND catheter**

Found:: : **804 total** | **22 journal results** | **599 preferred web results** | **183 other web results**

Sort by:: : **relevance** | **date**

☐ **1. IMBEDDED INTRAMUSCULAR IMPLANTS**

GAMBALE, Richard, A. / WEISER, Michael, F. / FORCUCCI, Stephen, J. / SHAH, Chirag, B. / C.R. BARD, INC., EUROPEAN PATENT, Oct 2001


...can include a **catheter**. Access to the **muscle** can take place by guiding a **catheter** delivery system...system. Once the **muscle** has been accessed...body formed of a **biocompatible** material and...include stimulating **angiogenesis** by enclosing...

Full text available at patent office. For more in-depth searching go to  **LexisNexis** similar results

☐ **2. SYSTEMS AND METHODS FOR IMBEDDED INTRAMUSCULAR IMPLANTS**

GAMBALE, Richard, A. / WEISER, Michael, F. / FORCUCCI, Stephen, J. / SHAH, Chirag, B. / C. R. BARD, INC., PATENT COOPERATION TREATY APPLICATION, Jun 2000

...can include a **catheter**. Access to the **muscle** can take place by guiding a **catheter** delivery system...system. Once the **muscle** has been accessed...body formed of a **biocompatible** material and...include stimulating **angiogenesis** by enclosing...

Full text available at patent office. For more in-depth searching go to  **LexisNexis** similar results

☐ **3. MODIFICATION OF PROPERTIES AND GEOMETRY OF HEART TISSUE TO INFLUENCE HEART FUNCTION**

JAYARAMAN, Swaminathan / JAYARAMAN, Swaminathan, PATENT COOPERATION TREATY APPLICATION, May 2003

...the use of skeletal **muscle** as the ventricular wrap...condition the skeletal **muscle**, 20 transforming it...passive device I made of **biocompatible** materials that is placed...removal of any heart **muscle**. Additional developments...describes implantable I **catheter** pump including a drive...

Full text available at patent office. For more in-depth searching go to  **LexisNexis** similar results

☐ **4. SYSTEM FOR TREATING ISCHEMIA**

CAFFERATA, Robert, L. / C.R. Bard Inc., EUROPEAN PATENT, Jul 2001

...balloon dilation **catheter** a drug delivery...of smooth **muscle**. The therapeutic...effected cells. A **catheter** based delivery...formed of a **biocompatible** material characterised...delivery of **angiogenesis** compounds...agent. The **biocompatible** material of...promoting **angiogenesis**. It is also...bioresorbable. The

Re
us
foi
co:
col
cor
do:
fibi
fibi
imj
imj
me
me
my
my
pol
pol
prc
res
Or
AI
f

catheter apparatus...

Full text available at patent office. For more in-depth searching go to  LexisNexis[®]
[similar results](#)

☐ 5. MEDICAL DEVICES AND METHODS FOR REGULATING THE TISSUE RESPONSE TO VASCULAR CLOSURE DEVICES

IYER, Sriram / KIPSHIDZE, Nicholas / NIKOLAYCHIK, Victor / ROUBIN, Gary / VASCULAR THERAPIES LLC, PATENT COOPERATION TREATY APPLICATION, Dec 2004

...of suitably **biocompatible** and substantially...of smooth **muscle** cells.

The...extracellular matrix, **angiogenesis** within the...by smooth **muscle** cells or myofibroblasts...VEGF), and **angiogenesis** within the...percutaneous **catheter**-based treatments...inhibit smooth **muscle** cell proliferation...well-known **biocompatible**, biodegradable...

Full text available at patent office. For more in-depth searching go to  LexisNexis[®]
[similar results](#)

☐ 6. METHOD AND APPARATUS FOR CELL AND ELECTRICAL THERAPY OF LIVING TISSUE

GIROUARD, Steven, D. / SALO, Rodney, W. / KENKNIGHT, Bruce, H. / CARDIAC PACEMAKERS, INC., PATENT COOPERATION TREATY APPLICATION, Jun 2004


...treat damaged heart **muscle** cells is to provide...treatment for damaged heart **muscle** is called "cell therapy...replacing damaged heart **muscle** or improving the mechanical...comprising one or more **catheter** leads with electrodes...cardiac function and **angiogenesis** are also discussed...

Full text available at patent office. For more in-depth searching go to  LexisNexis[®]
[similar results](#)

☐ 7. METHOD OF MODULATING ANGIOGENESIS

KANG, Keum, Yee / BEYER, Eric, C. / SEUL, Kyung, Hwan, PATENT COOPERATION TREATY APPLICATION, Nov 2003

...between smooth **muscle** cells is unregulated after balloon **catheter** injury in the rat...connexins regulate **angiogenesis** of blood vessels...endothelial and smooth **muscle** cells. Such novel...associated with **angiogenesis** including, without...

Full text available at patent office. For more in-depth searching go to  LexisNexis[®]
[similar results](#)

☐ 8. [mus9697.html](#) [215K]
Mar 1997

...effective. LIF was administered to **muscle** of the mdx mouse using osmotic...delivered into the vastus lateralis **muscle** at 7 U/ μ l for 7 days via a **catheter**. The results show that LIF increased the rate of **muscle** regeneration in mdx mice by stimulating...

[<http://www.iu.edu/~pietsch/mus9697.html>]
[similar results](#)

☐ 9. IMPLANTABLE SENSORS AND IMPLANTABLE PUMPS AND ANTI-SCARRING AGENTS

HUNTER, William, L. / GRAVETT, David, M. / TOLEIKIS, Philip, M. / MAITI, Arpita / ANGIOTECH INTERNATIONAL AG, PATENT COOPERATION TREATY APPLICATION, Jun 2005

...prevent the delivery **catheter** or sensor from being...particularly the drug delivery **catheter** lumen and the sensor...therapeutic agents from the **catheter** to the target tissue...fibroblasts or smooth **muscle** cells), deposition of...of new blood vessels (**angiogenesis**), and remodeling (maturation...

Full text available at patent office. For more in-depth searching go to  LexisNexis[®]
[similar results](#)

☐ 10. PATCH STABILIZATION OF RODS FOR TREATMENT OF CARDIAC MUSCLE

HELMUS, Michael, N. / SCIMED LIFE SYSTEMS, INC., PATENT COOPERATION TREATY APPLICATION, Oct 2003


...22, or interior **muscle** of the heart, through an inter-luminal **catheter** introduced into...treatment site of the **muscle**. **Catheter** 61 maybe introduced...distal end of the **catheter** 61. Alternatively...the patch to the **muscle** surface can be...

Full text available at patent office. For more in-depth searching go to  **LexisNexis**
[similar results](#)

- ☐ **11. USE OF COMPOSITIONS CONTAINING PDGF-BB FOR PROMOTING ANGIOGENESIS**
PAWLIUK, Robert / LEBOULCH, Philippe / GENETIX PHARMACEUTICALS, INC.,
PATENT COOPERATION TREATY APPLICATION, Aug 2002
 ...performed using a **catheter** based trans-myocardial...for promoting **angiogenesis** by
 contacting...gradient using a **biocompatible** material which...polymer Suitable
biocompatible materials include...embodiment, the **biocompatible** material
 is...comparing levels of **angiogenesis** in the Matrigel...the abdominal **muscle** adjacent
 to...

Full text available at patent office. For more in-depth searching go to  **LexisNexis**
[similar results](#)


- ☐ **12. MULTI-BALLOON DRUG DELIVERY CATHETER FOR ANGIOGENESIS**
FORMAN, Michael, Robert / EDWARDS LIFESCIENCES CORPORATION, PATENT
COOPERATION TREATY APPLICATION, Jan 2002
 ...relates generally to a **catheter** device and methods for...invention relates to a
catheter device utilizing multiple...vessels (therapeutic **angiogenesis**). The induction of
 new...agents into the heart **muscle** or vessels can result...recovery period than **catheter**
 based procedures. **Catheters**...

Full text available at patent office. For more in-depth searching go to  **LexisNexis**
[similar results](#)

- ☐ **13. Current status of catheter- and stent-based gene therapy**
Sharif, F. / Daly, K. / Crowley, J. / O'Brien, T., Cardiovascular Research, Nov 2004
 ...Expansion of the **catheter** in vivo has resulted...balloon expansion. This **catheter** has
 been used to deliver...to induce therapeutic **angiogenesis**. The plasmid DNA
 encoding...and superficial smooth **muscle** cells. They used an...with the use of these
catheters. Transgene expression...

Full text article available from  **SCIENCE DIRECT**
[similar results](#)

- ☐ **14. SYSTEMS AND METHODS FOR TREATING ISCHEMIA**
CAFFERATA, Robert, L. / C.R. BARD, INC., PATENT COOPERATION TREATY
APPLICATION, Mar 2000
 ...capable of promoting **angiogenesis**. In a further embodiment...a body formed of a
biocompatible material containing...therapeutic agent. The **biocompatible** material of
 the delivery...capable of promoting **angiogenesis**. In another embodiment...one
 embodiment of a **catheter** having a delivery...


Full text available at patent office. For more in-depth searching go to  **LexisNexis**
[similar results](#)

- ☐ **15. N-[5-[4-(4-METHYL-PIPERAZINO-METHYL)-BENZOYLAMIDO]-2-**
METHYLPHENYL]-4-(3-...
PRESCOTT, Margaret, Forney / FELDMAN, David, Louis / NOVARTIS AG, PATENT
COOPERATION TREATY APPLICATION, Sep 2003
 ...indwelling shunt, fistula or **catheter** in a subject in need...in which the cardiac **muscle**
 or other organs are...such as a large bore t **catheter**, into a vein in a mammal...and
 central venous **catheters**. Grafts are most commonly...proliferation of smooth **muscle**
 cells, and the abundance...

Full text available at patent office. For more in-depth searching go to  **LexisNexis**
[similar results](#)

- ☐ **16. ROTATABLE CATHETER ASSEMBLY**
EIDENSCHINK, Tracee / SCIMED LIFE SYSTEMS, INC., PATENT COOPERATION
TREATY APPLICATION, Sep 2005
 TITLE Rotatable **Catheter** Assembly CROSS-REFERENCE TO RELATED...medical device in
 the passage. Such **catheter** assemblies include those described...require a significant

portion of the **catheter** assembly in addition to the balloon...

Full text available at patent office. For more in-depth searching go to  LexisNexis
[similar results](#)

☐ 17. CELLULAR TRANSPLANTATION FOR HEART REGENERATION

LAW, Peter, K. / LAW, Peter, K., PATENT COOPERATION TREATY APPLICATION, Oct 2003


...healthy hearts, healthy **muscles**, as well as for diseased hearts and diseased **muscles**. In yet another embodiment...cardiomyocytes through a **catheter** pathway. Yet another...of damaged no heart **muscle**, comprising myoblasts...group consisting of an **angiogenesis** factor, vascular endothelial...

Full text available at patent office. For more in-depth searching go to  LexisNexis
[similar results](#)

☐ 18. METHODS AND REAGENTS FOR INHIBITING ANGIOGENESIS

GYURIS, Jenő / GPC BIOTECH INC., PATENT COOPERATION TREATY APPLICATION, Sep 2000

...endothelial cells undergoing **angiogenesis** is eventually resolved when...blood vessel. The process of **angiogenesis** is orchestrated by a complex...stromal cells (e.g., smooth **muscle** cells, pericytes, fibroblasts...metalloprotease-2) drive the process of **angiogenesis** through a predictable sequence...

Full text available at patent office. For more in-depth searching go to  LexisNexis
[similar results](#)

☐ 19. METHODS AND COMPOSITIONS FOR THE TREATMENT OF GRAFT FAILURE

SUKHATME, Vikas, P. / BETH ISRAEL DEACONESS MEDICAL CENTER, PATENT COOPERATION TREATY APPLICATION, Nov 2003


...by the migration of smooth **muscle** cells into the intima, by the proliferation of vascular smooth **muscle** cells, or by the deposition...the group consisting of: an **angiogenesis** inhibitor, an anti- proliferative...human aortic vascular smooth **muscle** cells in vitro with (i) an N-phenyl-2-pyrimidi...

Full text available at patent office. For more in-depth searching go to  LexisNexis
[similar results](#)

☐ 20. METHODS AND COMPOSITIONS TO TREAT MYOCARDIAL CONDITIONS

MICHAL, Eugene, T. / MANDRUSOV, Evgenia / CLAUDE, Charles, D. / DING, Ni / SIMHAMBHATLA, Murthy / HOSSAINY, Syed, Faiyez, Ahmed / SRIDHARAN, Srinivasan / (...) / GUIDANT CORPORATION, V.I., PATENT COOPERATION TREATY APPLICATION, Oct 2004

...even though the remaining **muscle** is strong enough to pump a...media layer is mostly smooth **muscle** cells and extracellular matrix...treatment agents may induce **angiogenesis**. In another...illustrates a few examples of **biocompatible** perfluorinated compounds...

Full text available at patent office. For more in-depth searching go to  LexisNexis
[similar results](#)

last 

Results Pages: [[<< Prev](#)] [1](#) [2](#) [3](#) [4](#) [5](#) [6](#) [7](#) [8](#) [9](#) [10](#) [11](#) [12](#) [13](#) [14](#) [15](#) [16](#) [17](#) [18](#) [19](#) [20](#) [[Next >>](#)] [back to top](#)

[Downloads](#) | [Subscribe to News Updates](#) | [User Feedback](#) | [Advertising](#)
[Test Zone](#) | [Tell A Friend](#) | [Terms Of Service](#) | [Privacy Policy](#) | [Legal](#)

Powered by FAST © Elsevier 2005

Basic Search

[Advanced Search](#) [Search Preferences](#)

Angiogenesis AND muscle AND biocompatible AND cati

Search

☒ Journal sources ☒ Preferred Web sources ☒ Other Web sources ☐ Exact phrase

Searched for:: :All of the words: **Angiogenesis AND muscle AND biocompatible AND catheter**



Found:: :**804 total** | **22 journal results** | **599 preferred web results** | **183 other web results**

Sort by:: :**relevance** | [date](#)

Save checked results

Email checked results

Export checked results

- ☐ **41. Development of Diabetes Mellitus in the West of Scotland Coronary** [PDF-920K]
 Apr 2004
 ...involved in FA turnover like **muscle** (skeletal and heart), adipose...Aorta and Activates a Smooth **Muscle** Cell Differentiation Program...critical regulator of smooth **muscle** cell (SMC)-restricted gene...pathophysiologic processes, such as **angiogenesis**, inflammation, cancer metastasis...
[\[http://vascular.stanford.edu/vasc_bio_lab/research/pdf...\]](http://vascular.stanford.edu/vasc_bio_lab/research/pdf...)
[similar results](#)
- ☐ **42. METHOD AND APPARATUS FOR DETECTING VULNERABLE ATHEROSCLEROTIC PLAQUE**
NAGHAVI, Morteza / VOLCANO THERAPEUTICS, INC., PATENT COOPERATION TREATY APPLICATION, Jul 2003
 ...less abundant smooth **muscle** cells and, consequentially...an infrared-sensing **catheter**, or other invasive or...infrared fiber optic **catheter** intended for measuring...they are not made of **biocompatible** material, and are therefore...Infrared fiber optic **catheter** designs must also take...
Full text available at patent office. For more in-depth searching go to  LexisNexis
[similar results](#)
- ☐ **43. INJECTABLE CROSS-LINKED POLYMERIC PREPARATIONS AND USES THEREOF**
COHEN, Smadar / LEOR, Jonathan / BEN-GURION UNIVERSITY OF THE NEGEV, PATENT COOPERATION TREATY APPLICATION, Nov 2004
 ...arrhythmias, and in therapeutic **angiogenesis**. The composition of the invention...that may promote cardiac **angiogenesis** and regeneration. In a yet...method of inducing therapeutic **angiogenesis**, comprising administering...electromechanical mapping or MRI guided **catheters**, and any percutaneous cardiac...
Full text available at patent office. For more in-depth searching go to  LexisNexis
[similar results](#)
- ☐ **44. BioMed Central | Full text | Therapeutic Angiogenesis Using Local Perivascular and Pericardial Delivery** [93K]
 Oct 2004
 ...Report Therapeutic **Angiogenesis** Using Local Perivascular...inducing therapeutic **angiogenesis**, we describe the characteristics...with the delivery **catheters** placed along an epicardial...useful for therapeutic **angiogenesis** [4 24 28 29 31 34...cytokines. The

Re
us
fo
co
col
cor
do
fib
fib
im
im
me
me
my
my
pol
pol
pro
res
Or
AI
f

use of **biocompatible** and bioabsorbable...

more hits from [<http://www.biomedcentral.com/1523-3839/2/213>]

[similar results](#)

45. A PRESSURE APRON DIRECT INJECTION CATHETER

MICKLEY, Timothy / SCIMED LIFE SYSTEMS, INC., PATENT COOPERATION TREATY APPLICATION, Sep 2003


...contraction of the heart **muscle**. This unintended and...neighboring tissue and **muscle**. Summary of the Invention...004] An injection **catheter** for direct injection...sectional view of the **catheter** from Fig. 1. In Fig...embodiment can be formed of **biocompatible** polymeric or metallic...

Full text available at patent office. For more in-depth searching go to  LexisNexis [similar results](#)

46. METHODS AND COMPOUNDS FOR THE TREATMENT OF VASCULAR STENOSIS

SUKHATME, Vikas, P. / BETH ISRAEL DEACONESS MEDICAL CENTER, PATENT COOPERATION TREATY APPLICATION, Dec 2004

...reduce vascular smooth **muscle** cell hyperplasia. In...group consisting of an **angiogenesis** inhibitor, an anti-proliferative...migration of smooth **muscle** cells into the intima...proliferation of vascular smooth **muscle** cells, or by the deposition...group consisting of: an **angiogenesis** inhibitor, an anti-proliferative...

Full text available at patent office. For more in-depth searching go to  LexisNexis [similar results](#)

47. BIFURCATED STENT DELIVERY SYSTEM

EIDENSCHINK, Tracee / WEBER, Jan / SCIMED LIFE SYSTEM, INC., PATENT COOPERATION TREATY APPLICATION, Aug 2005

...stent. Thus, a need exists to provide a **catheter** which is capable of allowing a medical...while also adequately protecting the **catheter** and/or balloon to which the stent is...herein address this need by providing a **catheter** system with a rotatable sheath apparatus...

Full text available at patent office. For more in-depth searching go to  LexisNexis [similar results](#)

48. gpragoale.PDF [PDF-257K]

Apr 2001

...Produce Produces Motor Benefits in Old Rats · Gene Therapy with VEGF121 Gene Transfer Stimulates **Angiogenesis** for Treatment of Peripheral **Muscle** Ischemia in Rats · The Impact of Hormone Replacement Therapy on Iron Status in Women · New Less... [<http://www1.od.nih.gov/gpra/gpragoaleFY2000.pdf>]

[similar results](#)

49. Biocompatibility evaluation of nickel-titanium shape memory metal alloy [PDF-255K]

Apr 1999

...surface treatment must consider. Keywords: NiTi, **biocompatible** materials, bone and **muscle** response, corrosio. Dedicated to my family Acknowledgements...42 2.8.2. **Muscle** response to NiTi...

more hits from [<http://herkules.oulu.fi/isbn9514252217/isbn9514252217....>]





[similar results](#)

50. FLOW REDUCING IMPLANT

BEN MUVHAR, Shmuel / SHALEV, Ilan / TSEHORI, Jonathan / DARVISH, Nissim / NEOVASC MEDICAL LTD., PATENT COOPERATION TREATY APPLICATION, Apr 2003

...arteries. One such mechanism is **angiogenesis**, in which new arteries are...bypassing the stenosis. Since **angiogenesis** sometimes does not occur naturally...use of a balloon expansion **catheter**, for example,! that exerts...provided by a standard balloon **catheter** that expands within the lumen...

Full text available at patent office. For more in-depth searching go to  LexisNexis [similar results](#)

- ☐ **51. IMPLANTABLE DRUG DELIVERY CATHETER SYSTEM WITH CAPILLARY INTERFACE**
JOSEPH, Jeffrey, I. / THOMAS JEFFERSON UNIVERSITY, PATENT COOPERATION TREATY APPLICATION, Feb 2001
IMPLANTABLE DRUG DELIVERY **CATHETER** SYSTEM WITH CAPILLARY INTERFACE...requires that a permanent IV **catheter** be maintained in a blood vessel...the drug supply, through the **catheter** and into the drug reservoir...system resides in the use of **biocompatible** three-dimensional scaffolds...
Full text available at patent office. For more in-depth searching go to  **LexisNexis**
[similar results](#)
- ☐ **52. Biodegradable nanoparticles for drug and gene delivery to cells and tissue**
Panyam, J. / Labhasetwar, V., Advanced Drug Delivery Reviews, Feb 2003
...therapeutic agents in **biocompatible** nanocomposites such...localized delivery using a **catheter**-based approach with...approved biodegradable and **biocompatible** polymers, poly (d,l...nanoparticles in vascular smooth **muscle** cells and in vascular...that in vascular smooth **muscle** cells, the nanoparticle...
Full text article available from  **ScienceDirect**
[similar results](#)
- ☐ **53. Medical Dictionary - Surgical Glossary - N [83K]**
May 2005
...to pelvic floor **muscle** weakness in women...pulses toward the **muscles** of the pelvic floor, causing the **muscles** to contract and...Neoretna (Æ-941) An **angiogenesis** inhibitor extracted...high-pressure PTCA balloon **catheter** Angioplasty **catheter**...
[more hits from \[http://www.mtdesk.com/n.shtml\]](http://www.mtdesk.com/n.shtml)
[similar results](#)
- ☐ **54. file:///Z:/database/html/110104UW.htm [PDF-2MB]**
Dec 2004
...option for patients who do not want or are not recommended for open heart surgery. The 3F Entrata Aortic Valve System adds **catheter** introduction capability to the 3F Aortic Bioprosthesis and is at the same stage of development qualification as our sutureless...
[more hits from \[http://www.newsrx.com/cgi-bin/samplepdf.cgi/?filename=...\]](http://www.newsrx.com/cgi-bin/samplepdf.cgi/?filename=...)
[similar results](#)
- ☐ **55. CATHETER AND IMPLANTS FOR THE DELIVERY OF THERAPEUTIC AGENTS TO TISSUES**
PALASIS, Maria / BARRY, James, J. / ELLIS, Louis / HENDRICKSON, Gary, L. / HARRISON, Kent, D. / WANG, Lixiao / BOSTON SCIENTIFIC LIMITED, PATENT COOPERATION TREATY APPLICATION, Jan 2003
...heart, delivered by a **catheter**. The tubes preferably...myocardium utilizing a **catheter** within the heart. In...vessels in healthy heart **muscle**. 5 A wound or series...which could promote **angiogenesis**, protect tissues (i...human heart having a PMR **catheter** inserted within, having...
Full text available at patent office. For more in-depth searching go to  **LexisNexis**
[similar results](#)
- ☐ **56. POLYMALIC ACID-BASED MULTIFUNCTIONAL DRUG DELIVERY SYSTEM**
LJUBIMOVA, Julia, Y. / BLACK, Keith, L. / HOLLER, Eggehard / ARROGENE, INC., PATENT COOPERATION TREATY APPLICATION, Jun 2005
A structured drug system that is useful for delivering a drug payload to a specific tissue or cell type is disclosed. The system is based on purified polymalic acid. This polymer isolated from natural sources is biocompatible, biodegradable and of...
Full text available at patent office. For more in-depth searching go to  **LexisNexis**
[similar results](#)
- ☐ **57. NICOTINE RECEPTOR AGONISTS IN STEM CELL AND PROGENITOR CELL RECRUITMENT**
COOKE, John, P. / JOHNSON, Frances, Lauri / PATHAK, Anjali / JANG, James / TSAO, Philip / HEESCHEN, Christopher / THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY, PATENT COOPERATION TREATY


APPLICATION, Sep 2005

...cell types. 0006] **Angiogenesis** and vasculogenesis...advantage. Stimulation of **angiogenesis** and/or vasculogenesis...cultured human smooth **muscle** cells," J Vase Surg...stimulates vascular smooth **muscle** cells to produce fibroblast...Volm et al. (1999) "Angiogenesis and cigarette smoking...

Full text available at patent office. For more in-depth searching go to  LexisNexis similar results

- ☐ 58. PHARMACEUTICAL COMPOSITIONS PREPARATION OF PEPTIDES, SECRETED BY THE SNAKE VENOM GLANDS, PARTICULAR OF BOTHROPS JARARACA,...
CAMARGO, Antô / nio / SANTOS, Robson / MILLÁ / N, Rubé / n / IANZER, Danielle / (...) / **UTICA LTDA.**, PATENT COOPERATION TREATY APPLICATION, Jun 2004

...atherosclerosis, mellitus diabetes and **angiogenesis**. (Yasumaru M, Tsuji S. Tsujii...Bouck NP. Captopril inhibits **angiogenesis** and slows the growth of...solution, I Iank's solution, I **biocompatible** saline solutions whether...limited to cyclodextrins, **biocompatible** polymers, biodegradable...

Full text available at patent office. For more in-depth searching go to  LexisNexis similar results


- ☐ 59. BIOCOMPATIBLE FLUORESCENT SILICON NANOPARTICLES
POSS, Kirtland, G. / MADDEN, Karen, N. / GROVES, Kevin / RAJOPADHYE, Milind / VISEN MEDICAL, INC., PATENT COOPERATION TREATY APPLICATION, Dec 2004

BIOCOMPATIBLE FLUORESCENT SILICON NANOPARTICLES RELATED APPLICATIONS...viva and in vitro imaging. Such agents preferably are **biocompatible**, are non- immunogenic, non toxic, and can be derivatized...INVENTION The present invention features compositions of **biocompatible** fluorescent silicon nanoparticles, and methods of...

Full text available at patent office. For more in-depth searching go to  LexisNexis similar results

- ☐ 60. DEVICES AND METHODS FOR TREATMENT OF STENOTIC REGIONS
BALBIR, Brar, S., Dr. / SAHOTA, Harvinder, Dr. / BALBIR, Brar, S., Dr., PATENT COOPERATION TREATY APPLICATION, Dec 2004

...of artery, or the use of **catheter**- mounted devices such as a balloon **catheter** to dilate the artery. The...fonned from any suitable **biocompatible** material. The balloon 114...removably attached to the **catheter** shaft 104 by affixing its...

Full text available at patent office. For more in-depth searching go to  LexisNexis similar results



Results Pages: [[<< Prev](#)] [1](#) [2](#) [3](#) [4](#) [5](#) [6](#) [7](#) [8](#) [9](#) [10](#) [11](#) [12](#) [13](#) [14](#) [15](#) [16](#) [17](#) [18](#) [19](#) [20](#) [[Next >>](#)] [back to top](#)

[Downloads](#) | [Subscribe to News Updates](#) | [User Feedback](#) | [Advertising](#)
[Test Zone](#) | [Tell A Friend](#) | [Terms Of Service](#) | [Privacy Policy](#) | [Legal](#)

Powered by FAST © Elsevier 2005


[About Us](#)
[Newsroom](#)
[Advisory Board](#)
[Submit Web Site](#)
[Search Tips](#)
[Contact Us](#)
[Basic Search](#)
[Advanced Search](#) [Search Preferences](#)

☒ Journal sources ☒ Preferred Web sources ☒ Other Web sources ☐ Exact phrase

Searched for:: :All of the words:**Angiogenesis AND muscle AND biocompatible AND catheter**

Found:: :**804 total** | **22 journal results** | **599 preferred web results** | **183 other web results**

Sort by:: :**relevance** | date

Refine your search using these key words found in the results

☐ **121.cnsprogrambook** [PDF-2MB]

Mar 2002

FOUNDING MEMBERS F. S. Barringer Leon M. Becker Carol A. Brown Bland W. Cannon Richard L. DeSaussure John W. Devanney Franklin Earnest III Edward M. Gates James R. Gay Philip D. Gordy Warren C.
[http://btc.mgh.harvard.edu/docs/cnsprogrambook.pdf]
[similar results](#)

☐ **122.BRP2002Booklet.indd** [PDF-377K]

Mar 2002

...3. Svetlana Shabalovskaya Design of **Biocompatible** Niti (Nitinol) Surfaces (NHLBI) 4. Buddy...Rakesh Jain Integrative Biology of Tumor **Angiogenesis**, Invasion And Metastasis (NCI) 7. Robert...Fredberg Micromechanics of Airway Smooth **Muscle** Cells in Culture (NHLBI) 9. Jay Humphrey...
[more hits from](#) [http://0-www.beacon.nih.gov.library.unl.edu/funded/brpw...]
[similar results](#)

☐ **123.eMedicine - Oral Hemangiomas : Article by Randall Wilk, DDS, PhD, MD**

[118K]

Jul 2005

...deeper into the subcutaneous layer, the **muscle**, or the bone tissue and give rise to...have been demonstrated as regulators of **angiogenesis** (Folkman, 1987). Takahashi has outlined...In the oral cavity, the bones and the **muscles** are affected as well as the mucosa and...
[more hits from](#) [http://www.emedicine.com/derm/topic810.htm]
[similar results](#)

☐ **124.D:\ abs\era2002\ e.DVI** [PDF-2MB]

Jun 2002

...INHIBITS PROLIFERATION OF VASCULAR SMOOTH **MUSCLE** CELLS THROUGH INHIBITING GENERATION OF...anti-hypertensive agent, can inhibit vascular smooth **muscle** cell (VSMC) proliferation, and therefore...angiotensin II receptor in vascular smooth **muscle** cell cultures

[coated](#)
[collagen](#)
[coronary](#)
[doxorubicin](#)
[fibrin](#)
[fibrosis](#)
[implantation](#)
[implants](#)
[medical device](#)
[methotrexate](#)
[myocardial](#)
[myocardium](#)
[polymeric](#)
[polypeptide](#)
[proximal](#)
[restenosis](#)

Or refine using:

of mesenteric arteries from...

more hits from [<http://www2.unipr.it/~eraedta/2002/images/poster%20ses...>]

similar results

☐ **125.** CD 3506.p65 [PDF-896K]

Jan 2004

1 Lerner Research Institute Scientific Report 2003-2004 Paul E. DiCorleto, Ph.D. The Sherwin-Page Chair Investigating Causes, Discovering Cures 2 Table of Contents FLOYD D. LOOP, M.D., CHAIRMAN, BOARD OF GOVERNORS

[http://www.ri.ccf.org/news/sr/documents/sr2003_04.pdf]

similar results

☐ **126.** Gene and cell - based therapies for heart disease [PDF-93K]

Aug 2004

...area. A variety of **catheter** types have been developed...Table 2).

Therapeutic **angiogenesis** by delivery of genes...specialized intraventricular **catheter**. In all cases, the...infusion with the aid of a **catheter** distributes the therapeutic...ischemia Therapeutic **angiogenesis** by exogenous supplementa...

[<http://www.mgm.ufl.edu/GMS6059/Reviews/Melo%20FASEB%20...>]

similar results

☐ **127.** D:\ abs\era2003\ e.DVI [PDF-115K]

Oct 2004

...relevant parameter to assay in the development of much more

biocompatible PD fluids. W685 DISFUNCTION OF PERITONEAL PHAGOCYTES RESPIRATORY...rats were set on a heating pad to maintain body temperature. **Catheters** were inserted into an artery and a vein for blood sampling...

[http://ndt.oupjournals.org/cgi/reprint/18/suppl_4/765....]

similar results

☐ **128.** JURIBE2003 vol3 no1.pmd [PDF-305K]

Nov 2004

...Lianne Lin, Vipin Kumar, Brian Flinn, Krishna Nadella 51 Over Expressing Integrin Beta_3 Increases Cellular Adhesion in Smooth **Muscle** Cells Lucy Lomas, Donald Courter, Ceci Giachelli 58 Determination of Lens Type Using a Cationic Dye Jill E. Martell, Stephanie...

[<http://www.uweb.engr.washington.edu/education/pdf/JURI...>]

similar results

☐ **129.** 2990v22i2093.indd [PDF-148K]

Jul 2005

...engineering, and Judah Folkman (Harvard University, US) on **angiogenesis** in cancer. Four mini Symposia have been planned and include...Tissue Engineering: Past and Future - Robert Langer, and **Angiogenesis** in Cancer - Judah Folkman. CRS draws members from all over...

[<http://www.controlledrelease.org/newsletter/v22i2.pdf>]

similar results

☐ **130.** 5606 CU OVPR TXT REV2 [PDF-146K]

Oct 2004

Cornell's Research Serves the Region and Beyond Office of the Vice Provost for Research 2004 Kionix SMALL BUSINESS DEVELOPMENT "Modern academic researchers have a unique opportunity to facilitate the transfer of exciting research ideas to commercial viability.

[<http://www.research.cornell.edu/vpr/sbg/sbg2004.pdf>]

similar results

☐ **131.** Task Force on Research in Pediatric Cardiovascular Disease [PDF-100K]

Feb 2003

...measures of vascular and **muscle** function. Surgeons and...types of therapy with **catheters**, and improved pre- and...potential source of heart **muscle** cells and blood vessels...need intervention, by **catheter** or surgically, during...myocardium, or heart **muscle**. These cardiomyopathies...

[http://www.stanford.edu/~draney/PDFs/pediatric_cvd.pdf]

similar results

☐ **132.** September 23, Monday [PDF-427K]

Jun 2003

...increased by co-culture with secretory smooth **muscle** cells G.E. Rainger
2 S1.5 Responses of...Synergetics of blood flow in exercising skeletal **muscle** in man: cooperative effects of rheology...vasoconstriction and mechanical effects of **muscle** pumps H. Schmid-Schönbein S10.3

Unusual...

[<http://www.akdeniz.edu.tr/icbicch/Abstract%20Book.pdf>]

similar results

☐ **133.** Cellular Responses of Bioabsorbable Polymeric Material and Guglielmi

Detachable Coil in Experimental Aneurysms -- Murayama et ... [109K]

Murayama, Y / Yuichi Murayama / MD Fernando / MD Satoshi / Tateshima, MD Nestor R, Apr 2005

...Bioabsorbable polymeric materials (BPMs) have been used as **biocompatible** agents such as sutures, implants, and recently as drug delivery...penicillin G intramuscularly. Via the transfemoral route, a 6F **catheter** was positioned in the common carotid artery, and 6 mL of...

[<http://stroke.ahajournals.org/cgi/content/full/33/4/11...>]

similar results

☐ **134.** Note : Within nine months from the publication of the mention of the grant of the European patent any person may give [PDF-53K]

Jul 2004

...normal vascular smooth **muscle** cells in the artery...characterized by vascular smooth **muscle** proliferation, migration...as tubings, shunts, **catheters**, artificial implants...typically made of a **biocompatible** metal, such as such...balloon angioplasty **catheter**, as is known in the...

[http://www.european-patent-office.org/correct/2004/04_...]

similar results

☐ **135.** Magnetic Resonance Imaging for in vivo assessment of tissue oxygen [45K]

Murali C. Krishna / Nallathamby Devasahayam / John A. Cook / Sankaran Subramanian / Periannan Kuppusamy, May 2002

...advancement of cancer treatment. Tumor **angiogenesis** and its relation to metastatic disease...evaluation of agents designed to inhibit **angiogenesis** (Folkman 1999), comprise an emerging...would be expected that inhibitors of **angiogenesis** would influence tissue oxygen levels...

more hits from [http://dels.nas.edu/ilar/jour_online/42_2/Krishna+Mich...]

similar results

☐ **136.** Clinical applications of EPR: overview and perspectives [PDF-89K]

Feb 2005

NMR IN BIOMEDICINE NMR Biomed. 2004;17:335351 Published online in Wiley InterScience (www.interscience.wiley.com). DOI:10.1002/nbm.911

Clinical applications of EPR: overview and perspectives Harold M.

[<http://pet.radiology.uiowa.edu/downloads/Xiang%20Wu%20...>]

similar results

☐ **137.2HAPI - MeSH Terms** [152K]

May 2005

...anesthetics, local aneuploidy angelman syndrome angina pectoris
angiogenesis factor angiomyolipoma angioneurotic edema angioplasty
angioplasty...bilirubin binding sites binding sites, antibody biochemistry
biocompatible materials bioflavonoids biogenesis biogenic monoamines
biolistics...

[<http://www.sdsc.edu/mpr/2hapi/mesh.html>]

[similar results](#)

☐ **138.Member Publications 2004** [211K]

Jun 2005

Abei Y, Nelson SS, Amberman BD, Hans MG. Comparing orthodontic treatment outcome between orthodontists and general dentists with the ABO index. Am J Orthod Dentofacial Orthop 126:544-548, 2004. Abrahams NA, MacLennan GT, Khoury JD, Ormsby AH, Tamboli P, Doglioni C, Schumacher B, Tickoo SK.

[<http://cancer.cwru.edu/research/Pubs%202004.htm>]

[similar results](#)

☐ **139.No Title** [PDF-49K]

Dec 2004

A NOVEL LOOK AT SPECIATION Chung-I Wu, Ph.D., Chair of the Department of Ecology and Evolution, has taken on the process of evolution at its genetic core.

[<http://www.bsd.uchicago.edu/pr/PeerReview24.pdf>]

[similar results](#)

☐ **140.CRADAs in the Database, March 1997, By Title** [103K]

Apr 2001

...of Two Formulations - PHS NIH NICHD Assessment of Skeletal **Muscle** Function as an Indication of Nutritional Status - Army MRDC...Diagnostics - Navy unknown Cardiac Repolarization - Army MRDC WRAIR **Catheters** and Medical Devices Compatible with Magnetic Resonance Imaging...

[<http://www.bioinfo.com/fbdcradatitles.html>]

[similar results](#)

fast

Results Pages: [[<< Prev](#)] [1](#) [2](#) [3](#) [4](#) [5](#) [6](#) [7](#) [8](#) [9](#) [10](#) [11](#) [12](#) [13](#) [14](#) [15](#) [16](#) [17](#) [18](#) [19](#) [20](#) [[Next >>](#)] [back to top](#)

[Downloads](#) | [Subscribe to News Updates](#) | [User Feedback](#) | [Advertising](#)
[Test Zone](#) | [Tell A Friend](#) | [Terms Of Service](#) | [Privacy Policy](#) | [Legal](#)

Powered by FAST © Elsevier 2005

Welcome to STN International! Enter x:x

PASSWORD:

* * * * * Welcome to STN International * * * * *

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * STN Columbus * * * * *

```
=> file caplus uspatful epfull medline japio biosis embase scisearch
COST IN U.S. DOLLARS                               SINCE FILE          TOTAL
                                                    ENTRY          SESSION
FULL ESTIMATED COST                               0.42             0.42
```

FILE 'CAPLUS' ENTERED AT 13:08:26 ON 11 NOV 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 13:08:26 ON 11 NOV 2005
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EPFULL' ENTERED AT 13:08:26 ON 11 NOV 2005
COPYRIGHT (C) 2005 European Patent Office / FIZ Karlsruhe

FILE 'MEDLINE' ENTERED AT 13:08:26 ON 11 NOV 2005

FILE 'JAPIO' ENTERED AT 13:08:26 ON 11 NOV 2005
COPYRIGHT (C) 2005 Japanese Patent Office (JPO)- JAPIO

FILE 'BIOSIS' ENTERED AT 13:08:26 ON 11 NOV 2005
Copyright (c) 2005 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 13:08:26 ON 11 NOV 2005
Copyright (c) 2005 Elsevier B.V. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 13:08:26 ON 11 NOV 2005
Copyright (c) 2005 The Thomson Corporation

=> s angiogen? and catheter? and muscle
L1 4635 ANGIOGEN? AND CATHETER? AND MUSCLE

=> s l1 and myocardia?
L2 2399 L1 AND MYOCARDIA?

=> s l2 and (drug delivery)
1 FILES SEARCHED...
L3 1321 L2 AND (DRUG DELIVERY)

=> s l3 and implant?
L4 1183 L3 AND IMPLANT?

=> s l4 and (cardiac catheter)
L5 11 L4 AND (CARDIAC CATHETER)

=> s l5 1-11 ibib abs
MISSING OPERATOR L5 1-11
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> d l5 1-11 ibib abs

L5 ANSWER 1 OF 11 USPATFULL on STN
ACCESSION NUMBER: 2005:3907 USPATFULL
TITLE: Injectable cross-linked polymeric preparations and uses
thereof
INVENTOR(S): Cohen, Smadar, Beer-Sheva, ISRAEL
Leor, Jonathan, Gane Tikva, ISRAEL
PATENT ASSIGNEE(S): BEN-GURION UNIVERSITY OF THE NEGEV, Beer-Sheva, ISRAEL
(non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005003010	A1	20050106
APPLICATION INFO.:	US 2004-840008	A1	20040505 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	IL 2003-155774	20030505
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MERCHANT & GOULD PC, P.O. BOX 2903, MINNEAPOLIS, MN, 55402-0903	
NUMBER OF CLAIMS:	49	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	24 Drawing Page(s)	
LINE COUNT:	1866	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A composition for promoting repair of damaged tissues, being a cross-linked alginate solution, which can be maintained in liquid form indefinitely (under constant conditions) and only gels in vivo. This cross-linked alginate solution is an ideal material to be used for tissue repair. Injection of said material into cardiac tissue post-myocardial infarct induced tissue regeneration. The invention provides such injectable solution, as well as compositions and method of preparation thereof. The invention also provides various methods and uses of the cross-linked alginate solution, for cardiac tissue regeneration, induction of neo-vascularization, enhancing SDF-1 expression and guiding stem cell chemotaxis, among others. A kit for tissue repair is also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 2 OF 11 USPATFULL on STN
 ACCESSION NUMBER: 2004:65957 USPATFULL
 TITLE: Expression of exogenous polynucleotide sequences in a vertebrate
 INVENTOR(S): Wolff, Jon A., Madison, WI, United States
 Duke, David J., Salem, OR, United States
 Felgner, Philip L., Rancho Santa Fe, CA, United States
 PATENT ASSIGNEE(S): Vical Incorporated, San Diego, CA, United States (U.S. corporation)
 Wisconsin Alumni Research Foundation, Madison, WI, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6706694	B1	20040316
APPLICATION INFO.:	US 2000-588655		20000606 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1997-979686, filed on 26 Nov 1997, now patented, Pat. No. US 6228844 Continuation of Ser. No. US 1995-480039, filed on 7 Jun 1995, now patented, Pat. No. US 5693622 Continuation of Ser. No. US 1994-210628, filed on 18 Mar 1994, now abandoned Continuation of Ser. No. US 1991-791101, filed on 12 Nov 1991, now abandoned Continuation-in-part of Ser. No. US 1995-486508, filed on 7 Jun 1995 Division of Ser. No. US 1990-496991, filed on 21 Mar 1990, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Wehbe, Anne M.		
LEGAL REPRESENTATIVE:	Sterne, Kessler, Goldstein & Fox P.L.L.C.		
NUMBER OF CLAIMS:	17		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	15 Drawing Figure(s); 9 Drawing Page(s)		
LINE COUNT:	3861		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a method for delivering a pharmaceutical

polypeptide to the interior of a cardiac cell of a vertebrate in vivo, comprising the step of introducing a preparation comprising a pharmaceutically acceptable injectable carrier and naked polynucleotide operatively coding for the polypeptide into the interstitial space of the heart, whereby the naked polynucleotide is taken up into the interior of the cell and has a pharmacological effect on the vertebrate. In a preferred embodiment wherein the polynucleotide encodes polypeptide immunologically foreign to the vertebrate, the delivery method preferably comprises delivering an immunosuppressive agent to the vertebrate to limit immune responses directed to the polypeptide.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 3 OF 11 USPATFULL on STN

ACCESSION NUMBER: 2003:265896 USPATFULL

TITLE: Expression of exogenous polynucleotide sequences in a vertebrate

INVENTOR(S): Wolff, Jon A., Madison, WI, UNITED STATES
Duke, David J., Salem, OR, UNITED STATES
Felgner, Philip L., Rancho Santa Fe, CA, UNITED STATES

PATENT ASSIGNEE(S): Vical Incorporated (U.S. corporation)
Wisconsin Alumni Research Foundation (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003186913	A1	20031002
APPLICATION INFO.:	US 2003-360645	A1	20030210 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-588655, filed on 6 Jun 2000, PENDING Continuation of Ser. No. US 1997-979686, filed on 26 Nov 1997, GRANTED, Pat. No. US 6228844 Continuation of Ser. No. US 1995-480039, filed on 7 Jun 1995, GRANTED, Pat. No. US 5693622 Continuation of Ser. No. US 1994-210628, filed on 18 Mar 1994, ABANDONED Continuation of Ser. No. US 1991-791101, filed on 12 Nov 1991, ABANDONED Division of Ser. No. US 1990-496991, filed on 21 Mar 1990, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	WO 1990-US1515	19900321
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	STERNE, KESSLER, GOLDSTEIN & FOX PLLC, 1100 NEW YORK AVENUE, N.W., WASHINGTON, DC, 20005	
NUMBER OF CLAIMS:	47	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	9 Drawing Page(s)	
LINE COUNT:	3217	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a method for delivering a pharmaceutical polypeptide to the interior of a cardiac cell of a vertebrate in vivo, comprising the step of introducing a preparation comprising a pharmaceutically acceptable injectable carrier and naked polynucleotide operatively coding for the polypeptide into the interstitial space of the heart, whereby the naked polynucleotide is taken up into the interior of the cell and has a pharmacological effect on the vertebrate. In a preferred embodiment wherein the polynucleotide encodes polypeptide immunologically foreign to the vertebrate, the delivery method preferably comprises delivering an immunosuppressive agent to the vertebrate to limit immune responses directed to the polypeptide.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 4 OF 11 USPATFULL on STN

ACCESSION NUMBER: 2003:238389 USPATFULL
TITLE: VEGF-D and **angiogenic** use thereof
INVENTOR(S): Oliviero, Salvatore, Siena, ITALY
PATENT ASSIGNEE(S): Chiron Corporation, Emeryville, PA (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003166547	A1	20030904
APPLICATION INFO.:	US 2002-174930	A1	20020619 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-640171, filed on 15 Aug 2000, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-149300P	19990816 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Chiron Corporation, Intellectual Property, P.O. Box 8097, Emeryville, CA, 94662-8097	
NUMBER OF CLAIMS:	22	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	11 Drawing Page(s)	
LINE COUNT:	1153	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

AB The present invention is directed to a method of inducing **angiogenesis** in a tissue in need of **angiogenesis**, comprising providing the tissue in need of **angiogenesis** with an **angiogenically** effective amount of a recombinant c-fos induced growth factor/vascular endothelial growth factor D (Fgf/Vegf-D), which is secreted factor of the VEGF family which binds to the vessel and lymphatic receptors VEGFR-2 and VEGFR-3 (VEGF-D). In another aspect, the present invention is directed to a method of inducing **angiogenesis** in an area in need of **angiogenesis** in a mammal comprising administering to said area in need of **angiogenesis** an **angiogenically** effective amount VEGF-D. The VEGF-D is provided or administered in solution of slow release form.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 5 OF 11 USPATFULL on STN

ACCESSION NUMBER: 2003:101978 USPATFULL
TITLE: **Drug delivery catheters**
INVENTOR(S): that attach to tissue and methods for their use
Altman, Peter A., South San Francisco, CA, United States
Hakem, Brian, South San Francisco, CA, United States
PATENT ASSIGNEE(S): BioCardia, Inc., San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6547787	B1	20030415
APPLICATION INFO.:	US 1999-418206		19991013 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1997-816850, filed on 13 Mar 1997		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Lateef, Marvin M.		
ASSISTANT EXAMINER:	Mercader, Eleni Mantis		
LEGAL REPRESENTATIVE:	Crockett, Esq., K. David, Crockett & Crockett		

NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 4
NUMBER OF DRAWINGS: 40 Drawing Figure(s); 15 Drawing Page(s)
LINE COUNT: 2046

AB A **drug delivery catheter** suited for cardiac procedures including transmyocardial revascularization. The **catheter** includes a distal helical coil or other fixation and penetrating element, which can be operated from the proximal end of the **catheter** to engage and penetrate the myocardium. Once delivered to the inside of the heart, the **catheter** can be used to created several helical wounds in the myocardium, and also inject small doses of therapeutic agents to the wounds. The TMR accomplished by the procedure provides for large wound to penetration ratio, and limits the potential of perforating the heart wall.

L5 ANSWER 6 OF 11 USPATFULL on STN

ACCESSION NUMBER: 2002:315281 USPATFULL

TITLE: **Drug delivery catheters**

that attach to tissue and methods for their use
INVENTOR(S): Altman, Peter A., South San Francisco, CA, UNITED STATES

Altman, John D., South San Francisco, CA, UNITED STATES
Stertz, Simon, South San Francisco, CA, UNITED STATES

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION:	US 2002177772	A1 20021128
---------------------	---------------	-------------

APPLICATION INFO.:	US 2002-190429	A1 20020705 (10)
--------------------	----------------	------------------

RELATED APPLN. INFO.:	Continuation of Ser. No. US 1999-418205, filed on 13 Oct 1999, GRANTED, Pat. No. US 6416510	
	Continuation-in-part of Ser. No. US 1997-816850, filed on 13 Mar 1997, GRANTED, Pat. No. US 6086582	

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: CROCKETT & CROCKETT, 24012 CALLE DE LA PLATA, SUITE 400, LAGUNA HILLS, CA, 92653

NUMBER OF CLAIMS: 15

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 15 Drawing Page(s)

LINE COUNT: 2055

AB A **drug delivery catheter** suited for cardiac procedures. The **catheter** includes a distal helical coil or other fixation and penetrating element which can be operated from the proximal end of the **catheter** to engage and penetrate the myocardium. Once delivered to the inside of the heart, the **catheter** can be used to inject small doses of therapeutic agents to the myocardium. The **drug delivery** system of the **catheter** allows for precise control of the dose injected into the heart wall.

L5 ANSWER 7 OF 11 USPATFULL on STN

ACCESSION NUMBER: 2002:167670 USPATFULL

TITLE: **Drug delivery catheters**

that attach to tissue and methods for their use

INVENTOR(S): Altman, Peter A., South San Francisco, CA, United States

Altman, John D., South San Francisco, CA, United States

Stertz, Simon, South San Francisco, CA, United States

PATENT ASSIGNEE(S): Biocardia, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6416510	B1	20020709
APPLICATION INFO.:	US 1999-418205		19991013 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1997-816850, filed on 13 Mar 1997		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Lateef, Marvin M.		
ASSISTANT EXAMINER:	Mercader, Eleni Mantis		
LEGAL REPRESENTATIVE:	Crockett, Esq., K. David, Crockett & Crockett		
NUMBER OF CLAIMS:	24		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	40 Drawing Figure(s); 15 Drawing Page(s)		
LINE COUNT:	2112		

AB A **drug delivery catheter** suited for cardiac procedures. The **catheter** includes a distal helical coil or other fixation and penetrating element which can be operated from the proximal end of the **catheter** to engage and penetrate the myocardium. Once delivered to the inside of the heart, the **catheter** can be used to inject small doses of therapeutic agents to the myocardium. The **drug delivery** system of the **catheter** allows for precise control of the dose injected into the heart wall.

L5 ANSWER 8 OF 11 USPATFULL on STN

ACCESSION NUMBER: 2001:225039 USPATFULL
 TITLE: **Implantable** device for penetrating and delivering agents to cardiac tissue
 INVENTOR(S): Altman, Peter A., 510 Clayton St., San Francisco, CA, United States 94117

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 37463	E1	20011211
	US 5551427		19960903 (Original)
APPLICATION INFO.:	US 1998-146120		19980901 (9)
	US 1995-387257		19950213 (Original)
DOCUMENT TYPE:	Reissue		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Dvorak, Linda C. M.		
ASSISTANT EXAMINER:	Ruddy, David M.		
LEGAL REPRESENTATIVE:	Larkin, Hoffman, Daly & Lindgren, Ltd., Niebuhr, Esq., Frederick W.		
NUMBER OF CLAIMS:	76		
EXEMPLARY CLAIM:	27		
NUMBER OF DRAWINGS:	22 Drawing Figure(s); 16 Drawing Page(s)		
LINE COUNT:	1539		

AB An **implantable** devices for the effective elimination of an arrhythmogenic site from the myocardium is presented. By inserting small biocompatible conductors and/or insulators into the heart tissue at the arrhythmogenic site, it is possible to effectively eliminate a portion of the tissue from the electric field and current paths within the heart. The device would act as an alternative to the standard techniques for the removal of tissue from the effective contribution to the hearts electrical action which require the destruction of tissue via energy transfer (RF, microwave, cryogenic, etc.). This device is a significant improvement in the state of the art in that it does not require tissue necrosis.

In one preferred embodiment the device is a non conductive helix that is permanently **implanted** into the heart wall around the

arrhythmogenic site. In variations on the embodiment, the structure is wholly or partially conductive, the structure is used as an **implantable** substrate for anti arrhythmic, inflammatory, or **angiogenic** pharmacological agents, and the structure is deliverable by a **catheter** with a disengaging stylet. In other preferred embodiments that may incorporate the same variations, the device is a straight or curved stake, or a group of such stakes that are inserted simultaneously.

L5 ANSWER 9 OF 11 USPATFULL on STN

ACCESSION NUMBER: 2001:67655 USPATFULL
 TITLE: Stimulating vascular growth by administration of DNA sequences encoding VEGF
 INVENTOR(S): Wolff, Jon A., Madison, WI, United States
 Duke, David J., Salem, OR, United States
 Felgner, Philip L., Rancho Santa Fe, CA, United States
 PATENT ASSIGNEE(S): Vical Incorporated, San Diego, CA, United States (U.S. corporation)
 Wisconsin Alumni Research Foundation, Madison, WI, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6228844	B1	20010508
APPLICATION INFO.:	US 1997-979686		19971126 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1995-480039, filed on 7 Jun 1995, now patented, Pat. No. US 5693622 Continuation of Ser. No. US 1994-210628, filed on 18 Mar 1994, now abandoned Continuation of Ser. No. US 1991-791101, filed on 12 Nov 1991, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Crouch, Deborah		
LEGAL REPRESENTATIVE:	Sterne, Kessler, Goldstein & Fox, P.L.L.C.		
NUMBER OF CLAIMS:	27		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	15 Drawing Figure(s); 9 Drawing Page(s)		
LINE COUNT:	3635		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a method for delivering a pharmaceutical polypeptide to the interior of a cardiac cell of a vertebrate in vivo, comprising the step of introducing a preparation comprising a pharmaceutically acceptable injectable carrier and naked polynucleotide operatively coding for the polypeptide into the interstitial space of the heart, whereby the naked polynucleotide is taken up into the interior of the cell and has a pharmacological effect on the vertebrate such as inducing vascular growth. In a preferred embodiment wherein the polynucleotide encodes polypeptide immunologically foreign to the vertebrate, the delivery method preferably comprises delivering an immunosuppressive agent to the vertebrate to limit immune responses directed to the polypeptide.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 10 OF 11 USPATFULL on STN

ACCESSION NUMBER: 97:112452 USPATFULL
 TITLE: Expression of exogenous polynucleotide sequences cardiac **muscle** of a mammal
 INVENTOR(S): Wolff, Jon A., Madison, WI, United States
 Duke, David J., Salem, OR, United States
 Felgner, Philip L., Rancho Santa Fe, CA, United States
 PATENT ASSIGNEE(S): Vical Incorporated, San Diego, CA, United States (U.S.

corporation)
Wisconsin Alumni Research Foundation, Madison, WI,
United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5693622		19971202
APPLICATION INFO.:	US 1995-480039		19950607 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1994-210628, filed on 18 Mar 1994, now abandoned which is a continuation of Ser. No. US 1991-791101, filed on 12 Nov 1991, now abandoned which is a continuation-in-part of Ser. No. US 1990-496991, filed on 21 Mar 1990, now abandoned which is a continuation-in-part of Ser. No. US 1990-467881, filed on 19 Jan 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-326305, filed on 21 Mar 1989, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Crouch, Deborah		
LEGAL REPRESENTATIVE:	Knobbe, Martens, Olson & Bear		
NUMBER OF CLAIMS:	23		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	16 Drawing Figure(s); 9 Drawing Page(s)		
LINE COUNT:	3250		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a method for delivering a pharmaceutical polypeptide to the interior of a cardiac cell of a vertebrate in vivo, comprising the step of introducing a preparation comprising a pharmaceutically acceptable injectable carrier and naked polynucleotide operatively coding for the polypeptide into the interstitial space of the heart, whereby the naked polynucleotide is taken up into the interior of the cell and has a pharmacological effect on the vertebrate. In a preferred embodiment wherein the polynucleotide encodes polypeptide immunologically foreign to the vertebrate, the delivery method preferably comprises delivering an immunosuppressive agent to the vertebrate to limit immune responses directed to the polypeptide.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 11 OF 11 USPATFULL on STN

ACCESSION NUMBER: 96:79305 USPATFULL

TITLE: **Implantable** device for the effective elimination of cardiac arrhythmogenic sites

INVENTOR(S): Altman, Peter A., 370 Altair Way Suite 302, Sunnyvale, CA, United States 94086

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5551427		19960903
APPLICATION INFO.:	US 1995-387257		19950213 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Sykes, Angela D.		
ASSISTANT EXAMINER:	Huang, Stephen D.		
LEGAL REPRESENTATIVE:	Niebuhr, Esq., Frederick W.		
NUMBER OF CLAIMS:	26		
EXEMPLARY CLAIM:	21		
NUMBER OF DRAWINGS:	22 Drawing Figure(s); 16 Drawing Page(s)		
LINE COUNT:	1261		

AB An **implantable** devices for the effective elimination of an arrhythmogenic site from the myocardium is presented. By inserting small biocompatible conductors and/or insulators into the heart tissue at the

arrhythmogenic site, it is possible to effectively eliminate a portion of the tissue from the electric field and current paths within the heart. The device would act as an alternative to the standard techniques for the removal of tissue from the effective contribution to the heart's electrical action which require the destruction of tissue via energy transfer (RF, microwave, cryogenic, etc.). This device is a significant improvement in the state of the art in that it does not require tissue necrosis.

In one preferred embodiment the device is a non conductive helix that is permanently **implanted** into the heart wall around the arrhythmogenic site. In variations on the embodiment, the structure is wholly or partially conductive, the structure is used as an **implantable** substrate for anti arrhythmic, inflammatory, or **angiogenic** pharmacological agents, and the structure is deliverable by a **catheter** with a disengaging stylet. In other preferred embodiments that may incorporate the same variations, the device is a straight or curved stake, or a group of such stakes that are inserted simultaneously.

Welcome to STN International! Enter x:x

PASSWORD:

* * * * * Welcome to STN International * * * * *

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * STN Columbus * * * * *

```
=> file caplus uspatful epfull medline japio biosis embase scisearch
COST IN U.S. DOLLARS                               SINCE FILE          TOTAL
                                                    ENTRY          SESSION
FULL ESTIMATED COST                                0.42            0.42
```

FILE 'CAPLUS' ENTERED AT 13:08:26 ON 11 NOV 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 13:08:26 ON 11 NOV 2005
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EPFULL' ENTERED AT 13:08:26 ON 11 NOV 2005
COPYRIGHT (C) 2005 European Patent Office / FIZ Karlsruhe

FILE 'MEDLINE' ENTERED AT 13:08:26 ON 11 NOV 2005

FILE 'JAPIO' ENTERED AT 13:08:26 ON 11 NOV 2005
COPYRIGHT (C) 2005 Japanese Patent Office (JPO)- JAPIO

FILE 'BIOSIS' ENTERED AT 13:08:26 ON 11 NOV 2005
Copyright (c) 2005 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 13:08:26 ON 11 NOV 2005
Copyright (c) 2005 Elsevier B.V. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 13:08:26 ON 11 NOV 2005
Copyright (c) 2005 The Thomson Corporation

=> s angiogen? and catheter? and muscle
L1 4635 ANGIOGEN? AND CATHETER? AND MUSCLE

=> s l1 and myocardia?
L2 2399 L1 AND MYOCARDIA?

=> s l2 and (drug delivery)
1 FILES SEARCHED...
L3 1321 L2 AND (DRUG DELIVERY)

=> s l3 and implant?
L4 1183 L3 AND IMPLANT?

=> s l4 and (cardiac catheter)
L5 11 L4 AND (CARDIAC CATHETER)

=> s l5 1-11 ibib abs
MISSING OPERATOR L5 1-11
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> d l5 1-11 ibib abs

L5 ANSWER 1 OF 11 USPATFULL on STN
ACCESSION NUMBER: 2005:3907 USPATFULL
TITLE: Injectable cross-linked polymeric preparations and uses
thereof
INVENTOR(S): Cohen, Smadar, Beer-Sheva, ISRAEL
Leor, Jonathan, Gane Tikva, ISRAEL
PATENT ASSIGNEE(S): BEN-GURION UNIVERSITY OF THE NEGEV, Beer-Sheva, ISRAEL
(non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005003010	A1	20050106
APPLICATION INFO.:	US 2004-840008	A1	20040505 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	IL 2003-155774	20030505
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MERCHANT & GOULD PC, P.O. BOX 2903, MINNEAPOLIS, MN, 55402-0903	
NUMBER OF CLAIMS:	49	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	24 Drawing Page(s)	
LINE COUNT:	1866	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A composition for promoting repair of damaged tissues, being a cross-linked alginate solution, which can be maintained in liquid form indefinitely (under constant conditions) and only gels in vivo. This cross-linked alginate solution is an ideal material to be used for tissue repair. Injection of said material into cardiac tissue post-myocardial infarct induced tissue regeneration. The invention provides such injectable solution, as well as compositions and method of preparation thereof. The invention also provides various methods and uses of the cross-linked alginate solution, for cardiac tissue regeneration, induction of neo-vascularization, enhancing SDF-1 expression and guiding stem cell chemotaxis, among others. A kit for tissue repair is also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 2 OF 11 USPATFULL on STN
 ACCESSION NUMBER: 2004:65957 USPATFULL
 TITLE: Expression of exogenous polynucleotide sequences in a vertebrate
 INVENTOR(S): Wolff, Jon A., Madison, WI, United States
 Duke, David J., Salem, OR, United States
 Felgner, Philip L., Rancho Santa Fe, CA, United States
 PATENT ASSIGNEE(S): Vical Incorporated, San Diego, CA, United States (U.S. corporation)
 Wisconsin Alumni Research Foundation, Madison, WI, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6706694	B1	20040316
APPLICATION INFO.:	US 2000-588655		20000606 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1997-979686, filed on 26 Nov 1997, now patented, Pat. No. US 6228844 Continuation of Ser. No. US 1995-480039, filed on 7 Jun 1995, now patented, Pat. No. US 5693622 Continuation of Ser. No. US 1994-210628, filed on 18 Mar 1994, now abandoned Continuation of Ser. No. US 1991-791101, filed on 12 Nov 1991, now abandoned Continuation-in-part of Ser. No. US 1995-486508, filed on 7 Jun 1995 Division of Ser. No. US 1990-496991, filed on 21 Mar 1990, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Wehbe , Anne M.		
LEGAL REPRESENTATIVE:	Sterne, Kessler, Goldstein & Fox P.L.L.C.		
NUMBER OF CLAIMS:	17		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	15 Drawing Figure(s); 9 Drawing Page(s)		
LINE COUNT:	3861		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a method for delivering a pharmaceutical

polypeptide to the interior of a cardiac cell of a vertebrate in vivo, comprising the step of introducing a preparation comprising a pharmaceutically acceptable injectable carrier and naked polynucleotide operatively coding for the polypeptide into the interstitial space of the heart, whereby the naked polynucleotide is taken up into the interior of the cell and has a pharmacological effect on the vertebrate. In a preferred embodiment wherein the polynucleotide encodes polypeptide immunologically foreign to the vertebrate, the delivery method preferably comprises delivering an immunosuppressive agent to the vertebrate to limit immune responses directed to the polypeptide.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 3 OF 11 USPATFULL on STN

ACCESSION NUMBER: 2003:265896 USPATFULL

TITLE: Expression of exogenous polynucleotide sequences in a vertebrate

INVENTOR(S): Wolff, Jon A., Madison, WI, UNITED STATES
Duke, David J., Salem, OR, UNITED STATES
Felgner, Philip L., Rancho Santa Fe, CA, UNITED STATES

PATENT ASSIGNEE(S): Vical Incorporated (U.S. corporation)
Wisconsin Alumni Research Foundation (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003186913	A1	20031002
APPLICATION INFO.:	US 2003-360645	A1	20030210 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-588655, filed on 6 Jun 2000, PENDING Continuation of Ser. No. US 1997-979686, filed on 26 Nov 1997, GRANTED, Pat. No. US 6228844 Continuation of Ser. No. US 1995-480039, filed on 7 Jun 1995, GRANTED, Pat. No. US 5693622 Continuation of Ser. No. US 1994-210628, filed on 18 Mar 1994, ABANDONED Continuation of Ser. No. US 1991-791101, filed on 12 Nov 1991, ABANDONED Division of Ser. No. US 1990-496991, filed on 21 Mar 1990, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	WO 1990-US1515	19900321
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	STERNE, KESSLER, GOLDSTEIN & FOX PLLC, 1100 NEW YORK AVENUE, N.W., WASHINGTON, DC, 20005	
NUMBER OF CLAIMS:	47	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	9 Drawing Page(s)	
LINE COUNT:	3217	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a method for delivering a pharmaceutical polypeptide to the interior of a cardiac cell of a vertebrate in vivo, comprising the step of introducing a preparation comprising a pharmaceutically acceptable injectable carrier and naked polynucleotide operatively coding for the polypeptide into the interstitial space of the heart, whereby the naked polynucleotide is taken up into the interior of the cell and has a pharmacological effect on the vertebrate. In a preferred embodiment wherein the polynucleotide encodes polypeptide immunologically foreign to the vertebrate, the delivery method preferably comprises delivering an immunosuppressive agent to the vertebrate to limit immune responses directed to the polypeptide.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 4 OF 11 USPATFULL on STN

ACCESSION NUMBER: 2003:238389 USPATFULL
TITLE: VEGF-D and **angiogenic** use thereof
INVENTOR(S): Oliviero, Salvatore, Siena, ITALY
PATENT ASSIGNEE(S): Chiron Corporation, Emeryville, PA (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003166547	A1	20030904
APPLICATION INFO.:	US 2002-174930	A1	20020619 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-640171, filed on 15 Aug 2000, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-149300P	19990816 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Chiron Corporation, Intellectual Property, P.O. Box 8097, Emeryville, CA, 94662-8097	
NUMBER OF CLAIMS:	22	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	11 Drawing Page(s)	
LINE COUNT:	1153	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

AB The present invention is directed to a method of inducing **angiogenesis** in a tissue in need of **angiogenesis**, comprising providing the tissue in need of **angiogenesis** with an **angiogenically** effective amount of a recombinant c-fos induced growth factor/vascular endothelial growth factor D (Figf/Vegf-D), which is secreted factor of the VEGF family which binds to the vessel and lymphatic receptors VEGFR-2 and VEGFR-3 (VEGF-D). In another aspect, the present invention is directed to a method of inducing **angiogenesis** in an area in need of **angiogenesis** in a mammal comprising administering to said area in need of **angiogenesis** an **angiogenically** effective amount VEGF-D. The VEGF-D is provided or administered in solution of slow release form.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 5 OF 11 USPATFULL on STN

ACCESSION NUMBER: 2003:101978 USPATFULL
TITLE: **Drug delivery catheters**
that attach to tissue and methods for their use
INVENTOR(S): Altman, Peter A., South San Francisco, CA, United States
Hakem, Brian, South San Francisco, CA, United States
PATENT ASSIGNEE(S): BioCardia, Inc., San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6547787	B1	20030415
APPLICATION INFO.:	US 1999-418206		19991013 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1997-816850, filed on 13 Mar 1997		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Lateef, Marvin M.		
ASSISTANT EXAMINER:	Mercader, Eleni Mantis		
LEGAL REPRESENTATIVE:	Crockett, Esq., K. David, Crockett & Crockett		

NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 4
NUMBER OF DRAWINGS: 40 Drawing Figure(s); 15 Drawing Page(s)
LINE COUNT: 2046

AB A **drug delivery catheter** suited for cardiac procedures including transmyocardial revascularization. The **catheter** includes a distal helical coil or other fixation and penetrating element, which can be operated from the proximal end of the **catheter** to engage and penetrate the myocardium. Once delivered to the inside of the heart, the **catheter** can be used to created several helical wounds in the myocardium, and also inject small doses of therapeutic agents to the wounds. The TMR accomplished by the procedure provides for large wound to penetration ratio, and limits the potential of perforating the heart wall.

L5 ANSWER 6 OF 11 USPATFULL on STN

ACCESSION NUMBER: 2002:315281 USPATFULL

TITLE: **Drug delivery catheters**

INVENTOR(S): that attach to tissue and methods for their use
Altman, Peter A., South San Francisco, CA, UNITED STATES

Altman, John D., South San Francisco, CA, UNITED STATES
Stertz, Simon, South San Francisco, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002177772	A1	20021128
APPLICATION INFO.:	US 2002-190429	A1	20020705 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1999-418205, filed on 13 Oct 1999, GRANTED, Pat. No. US 6416510 Continuation-in-part of Ser. No. US 1997-816850, filed on 13 Mar 1997, GRANTED, Pat. No. US 6086582		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	CROCKETT & CROCKETT, 24012 CALLE DE LA PLATA, SUITE 400, LAGUNA HILLS, CA, 92653		
NUMBER OF CLAIMS:	15		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	15 Drawing Page(s)		
LINE COUNT:	2055		

AB A **drug delivery catheter** suited for cardiac procedures. The **catheter** includes a distal helical coil or other fixation and penetrating element which can be operated from the proximal end of the **catheter** to engage and penetrate the myocardium. Once delivered to the inside of the heart, the **catheter** can be used to inject small doses of therapeutic agents to the myocardium. The **drug delivery** system of the **catheter** allows for precise control of the dose injected into the heart wall.

L5 ANSWER 7 OF 11 USPATFULL on STN

ACCESSION NUMBER: 2002:167670 USPATFULL

TITLE: **Drug delivery catheters**

INVENTOR(S): that attach to tissue and methods for their use
Altman, Peter A., South San Francisco, CA, United States

Altman, John D., South San Francisco, CA, United States
Stertz, Simon, South San Francisco, CA, United States

PATENT ASSIGNEE(S): Biocardia, Inc., South San Francisco, CA, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6416510	B1	20020709
APPLICATION INFO.:	US 1999-418205		19991013 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1997-816850, filed on 13 Mar 1997		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Lateef, Marvin M.		
ASSISTANT EXAMINER:	Mercader, Eleni Mantis		
LEGAL REPRESENTATIVE:	Crockett, Esq., K. David, Crockett & Crockett		
NUMBER OF CLAIMS:	24		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	40 Drawing Figure(s); 15 Drawing Page(s)		
LINE COUNT:	2112		

AB A **drug delivery catheter** suited for cardiac procedures. The **catheter** includes a distal helical coil or other fixation and penetrating element which can be operated from the proximal end of the **catheter** to engage and penetrate the myocardium. Once delivered to the inside of the heart, the **catheter** can be used to inject small doses of therapeutic agents to the myocardium. The **drug delivery** system of the **catheter** allows for precise control of the dose injected into the heart wall.

L5 ANSWER 8 OF 11 USPATFULL on STN
 ACCESSION NUMBER: 2001:225039 USPATFULL
 TITLE: **Implantable** device for penetrating and delivering agents to cardiac tissue
 INVENTOR(S): Altman, Peter A., 510 Clayton St., San Francisco, CA, United States 94117

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 37463	E1	20011211
	US 5551427		19960903 (Original)
APPLICATION INFO.:	US 1998-146120		19980901 (9)
	US 1995-387257		19950213 (Original)
DOCUMENT TYPE:	Reissue		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Dvorak, Linda C. M.		
ASSISTANT EXAMINER:	Ruddy, David M.		
LEGAL REPRESENTATIVE:	Larkin, Hoffman, Daly & Lindgren, Ltd., Niebuhr, Esq., Frederick W.		
NUMBER OF CLAIMS:	76		
EXEMPLARY CLAIM:	27		
NUMBER OF DRAWINGS:	22 Drawing Figure(s); 16 Drawing Page(s)		
LINE COUNT:	1539		

AB An **implantable** devices for the effective elimination of an arrhythmogenic site from the myocardium is presented. By inserting small biocompatible conductors and/or insulators into the heart tissue at the arrhythmogenic site, it is possible to effectively eliminate a portion of the tissue from the electric field and current paths within the heart. The device would act as an alternative to the standard techniques for the removal of tissue from the effective contribution to the hearts electrical action which require the destruction of tissue via energy transfer (RF, microwave, cryogenic, etc.). This device is a significant improvement in the state of the art in that it does not require tissue necrosis.

In one preferred embodiment the device is a non conductive helix that is permanently **implanted** into the heart wall around the

arrhythmogenic site. In variations on the embodiment, the structure is wholly or partially conductive, the structure is used as an **implantable** substrate for anti arrhythmic, inflammatory, or **angiogenic** pharmacological agents, and the structure is deliverable by a **catheter** with a disengaging stylet. In other preferred embodiments that may incorporate the same variations, the device is a straight or curved stake, or a group of such stakes that are inserted simultaneously.

L5 ANSWER 9 OF 11 USPATFULL on STN

ACCESSION NUMBER: 2001:67655 USPATFULL
TITLE: Stimulating vascular growth by administration of DNA sequences encoding VEGF
INVENTOR(S): Wolff, Jon A., Madison, WI, United States
Duke, David J., Salem, OR, United States
Felgner, Philip L., Rancho Santa Fe, CA, United States
PATENT ASSIGNEE(S): Vical Incorporated, San Diego, CA, United States (U.S. corporation)
Wisconsin Alumni Research Foundation, Madison, WI, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6228844	B1	20010508
APPLICATION INFO.:	US 1997-979686		19971126 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1995-480039, filed on 7 Jun 1995, now patented, Pat. No. US 5693622 Continuation of Ser. No. US 1994-210628, filed on 18 Mar 1994, now abandoned Continuation of Ser. No. US 1991-791101, filed on 12 Nov 1991, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Crouch, Deborah		
LEGAL REPRESENTATIVE:	Sterne, Kessler, Goldstein & Fox, P.L.L.C.		
NUMBER OF CLAIMS:	27		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	15 Drawing Figure(s); 9 Drawing Page(s)		
LINE COUNT:	3635		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a method for delivering a pharmaceutical polypeptide to the interior of a cardiac cell of a vertebrate in vivo, comprising the step of introducing a preparation comprising a pharmaceutically acceptable injectable carrier and naked polynucleotide operatively coding for the polypeptide into the interstitial space of the heart, whereby the naked polynucleotide is taken up into the interior of the cell and has a pharmacological effect on the vertebrate such as inducing vascular growth. In a preferred embodiment wherein the polynucleotide encodes polypeptide immunologically foreign to the vertebrate, the delivery method preferably comprises delivering an immunosuppressive agent to the vertebrate to limit immune responses directed to the polypeptide.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 10 OF 11 USPATFULL on STN

ACCESSION NUMBER: 97:112452 USPATFULL
TITLE: Expression of exogenous polynucleotide sequences cardiac **muscle** of a mammal
INVENTOR(S): Wolff, Jon A., Madison, WI, United States
Duke, David J., Salem, OR, United States
Felgner, Philip L., Rancho Santa Fe, CA, United States
PATENT ASSIGNEE(S): Vical Incorporated, San Diego, CA, United States (U.S.

corporation)
Wisconsin Alumni Research Foundation, Madison, WI,
United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5693622		19971202
APPLICATION INFO.:	US 1995-480039		19950607 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1994-210628, filed on 18 Mar 1994, now abandoned which is a continuation of Ser. No. US 1991-791101, filed on 12 Nov 1991, now abandoned which is a continuation-in-part of Ser. No. US 1990-496991, filed on 21 Mar 1990, now abandoned which is a continuation-in-part of Ser. No. US 1990-467881, filed on 19 Jan 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-326305, filed on 21 Mar 1989, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Crouch, Deborah		
LEGAL REPRESENTATIVE:	Knobbe, Martens, Olson & Bear		
NUMBER OF CLAIMS:	23		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	16 Drawing Figure(s); 9 Drawing Page(s)		
LINE COUNT:	3250		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a method for delivering a pharmaceutical polypeptide to the interior of a cardiac cell of a vertebrate in vivo, comprising the step of introducing a preparation comprising a pharmaceutically acceptable injectable carrier and naked polynucleotide operatively coding for the polypeptide into the interstitial space of the heart, whereby the naked polynucleotide is taken up into the interior of the cell and has a pharmacological effect on the vertebrate. In a preferred embodiment wherein the polynucleotide encodes polypeptide immunologically foreign to the vertebrate, the delivery method preferably comprises delivering an immunosuppressive agent to the vertebrate to limit immune responses directed to the polypeptide.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 11 OF 11 USPATFULL on STN

ACCESSION NUMBER: 96:79305 USPATFULL

TITLE: **Implantable** device for the effective elimination of cardiac arrhythmogenic sites

INVENTOR(S): Altman, Peter A., 370 Altair Way Suite 302, Sunnyvale, CA, United States 94086

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5551427		19960903
APPLICATION INFO.:	US 1995-387257		19950213 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Sykes, Angela D.		
ASSISTANT EXAMINER:	Huang, Stephen D.		
LEGAL REPRESENTATIVE:	Niebuhr, Esq., Frederick W.		
NUMBER OF CLAIMS:	26		
EXEMPLARY CLAIM:	21		
NUMBER OF DRAWINGS:	22 Drawing Figure(s); 16 Drawing Page(s)		
LINE COUNT:	1261		

AB An **implantable** devices for the effective elimination of an arrhythmogenic site from the myocardium is presented. By inserting small biocompatible conductors and/or insulators into the heart tissue at the

arrhythmogenic site, it is possible to effectively eliminate a portion of the tissue from the electric field and current paths within the heart. The device would act as an alternative to the standard techniques for the removal of tissue from the effective contribution to the hearts electrical action which require the destruction of tissue via energy transfer (RF, microwave, cryogenic, etc.). This device is a significant improvement in the state of the art in that it does not require tissue necrosis.

In one preferred embodiment the device is a non conductive helix that is permanently **implanted** into the heart wall around the arrhythmogenic site. In variations on the embodiment, the structure is wholly or partially conductive, the structure is used as an **implantable** substrate for anti arrhythmic, inflammatory, or **angiogenic** pharmacological agents, and the structure is deliverable by a **catheter** with a disengaging stylet. In other preferred embodiments that may incorporate the same variations, the device is a straight or curved stake, or a group of such stakes that are inserted simultaneously.

Welcome to STN International! Enter x:x

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	JUL 20	Powerful new interactive analysis and visualization software, STN AnaVist, now available
NEWS	4	AUG 11	STN AnaVist workshops to be held in North America
NEWS	5	AUG 30	CA/Caplus -Increased access to 19th century research documents
NEWS	6	AUG 30	CASREACT - Enhanced with displayable reaction conditions
NEWS	7	SEP 09	ACD predicted properties enhanced in REGISTRY/ZREGISTRY
NEWS	8	OCT 03	MATHDI removed from STN
NEWS	9	OCT 04	CA/Caplus-Canadian Intellectual Property Office (CIPO) added to core patent offices
NEWS	10	OCT 06	STN AnaVist workshops to be held in North America
NEWS	11	OCT 13	New CAS Information Use Policies Effective October 17, 2005
NEWS	12	OCT 17	STN(R) AnaVist(TM), Version 1.01, allows the export/download of Caplus documents for use in third-party analysis and visualization tools
NEWS	13	OCT 27	Free KWIC format extended in full-text databases
NEWS	14	OCT 27	DIOGENES content streamlined
NEWS	15	OCT 27	EPFULL enhanced with additional content

NEWS EXPRESS JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial' and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 13:57:26 ON 11 NOV 2005

```
=> file caplus uspatful epfull medline japio biosis embase scisearch
COST IN U.S. DOLLARS                               SINCE FILE          TOTAL
                                                    ENTRY          SESSION
FULL ESTIMATED COST                               0.21             0.21
```

FILE 'CAPLUS' ENTERED AT 13:58:15 ON 11 NOV 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN.CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 13:58:15 ON 11 NOV 2005
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EPFULL' ENTERED AT 13:58:15 ON 11 NOV 2005
COPYRIGHT (C) 2005 European Patent Office / FIZ Karlsruhe

FILE 'MEDLINE' ENTERED AT 13:58:15 ON 11 NOV 2005

FILE 'JAPIO' ENTERED AT 13:58:15 ON 11 NOV 2005
COPYRIGHT (C) 2005 Japanese Patent Office (JPO)- JAPIO

FILE 'BIOSIS' ENTERED AT 13:58:15 ON 11 NOV 2005
Copyright (c) 2005 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 13:58:15 ON 11 NOV 2005
Copyright (c) 2005 Elsevier B.V. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 13:58:15 ON 11 NOV 2005
Copyright (c) 2005 The Thomson Corporation

=> s catheter# and myocardi? and nitinol
L1 1625 CATHETER# AND MYOCARDI? AND NITINOL

=> s l1 and angiogen?
L2 356 L1 AND ANGIOGEN?

=> s l2 and (heat sensitive)
L3 59 L2 AND (HEAT SENSITIVE)

=> s l3 and muscle
L4 59 L3 AND MUSCLE

=> s l4 and (drug delivery)
1 FILES SEARCHED...
L5 59 L4 AND (DRUG DELIVERY)

=> s l5 and (thermal or shape) and memory
L6 59 L5 AND (THERMAL OR SHAPE) AND MEMORY

=> d l6 1-59 ibib abs

L6 ANSWER 1 OF 59 USPATFULL on STN
ACCESSION NUMBER: 2005:286512 USPATFULL
TITLE: Coated aneurysmal repair device
INVENTOR(S): Chen, Chao C., Edison, NJ, UNITED STATES
Falotico, Robert, Belle Mead, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005249776	A1	20051110
APPLICATION INFO.:	US 2005-149466	A1	20050609 (11)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2003-742346, filed on 19 Dec 2003, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	PHILIP S. JOHNSON, JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003, US		

NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 52 Drawing Page(s)
LINE COUNT: 6173

AB Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological organism's reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and/or compounds may be utilized to promote healing, including the formation of blood clots. The drugs, agents, and/or compounds may also be utilized to treat specific diseases, including vulnerable plaque. Therapeutic agents may also be delivered to the region of a disease site. In regional delivery, liquid formulations may be desirable to increase the efficacy and deliverability of the particular drug. Also, the devices may be modified to promote endothelialization. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until delivered and positioned. In addition, the devices utilized to deliver the implantable medical devices may be modified to reduce the potential for damaging the implantable medical device during deployment. Medical devices include stents, grafts, anastomotic devices, perivascular wraps, sutures and staples. In addition, various polymer combinations may be utilized to control the elution rates of the therapeutic drugs, agents and/or compounds from the implantable medical devices.

L6 ANSWER 2 OF 59 USPATFULL on STN

ACCESSION NUMBER: 2005:286511 USPATFULL

TITLE: Intraluminal medical devices in combination with therapeutic agents

INVENTOR(S): Falotico, Robert, Belle Mead, NJ, UNITED STATES
Narayanan, Pallassana, Belle Mead, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005249775	A1	20051110
APPLICATION INFO.:	US 2005-131720	A1	20050518 (11)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2003-742346, filed on 19 Dec 2003, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	PHILIP S. JOHNSON, JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003, US		
NUMBER OF CLAIMS:	26		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	52 Drawing Page(s)		
LINE COUNT:	6148		

AB Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological organism's reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and/or compounds may be utilized to promote healing, including the formation of blood clots. The drugs, agents, and/or compounds may

also be utilized to treat specific diseases, including vulnerable plaque. Therapeutic agents may also be delivered to the region of a disease site. In regional delivery, liquid formulations may be desirable to increase the efficacy and deliverability of the particular drug. Also, the devices may be modified to promote endothelialization. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until delivered and positioned. In addition, the devices utilized to deliver the implantable medical devices may be modified to reduce the potential for damaging the implantable medical device during deployment. Medical devices include stents, grafts, anastomotic devices, perivascular wraps, sutures and staples. In addition, various polymer combinations may be utilized to control the elution rates of the therapeutic drugs, agents and/or compounds from the implantable medical devices.

L6 ANSWER 3 OF 59 USPATFULL on STN

ACCESSION NUMBER: 2005:267649 USPATFULL

TITLE: Local administration of a combination of rapamycin and 17 beta-estradiol for the treatment of vulnerable plaque

INVENTOR(S): Falotico, Robert, Belle Mead, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005232965	A1	20051020
APPLICATION INFO.:	US 2004-826058	A1	20040415 (10)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	PHILIP S. JOHNSON, JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003, US		
NUMBER OF CLAIMS:	5		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	51 Drawing Page(s)		
LINE COUNT:	6130		

AB Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological organism's reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and/or compounds may be utilized to promote healing, including the formation of blood clots. The drugs, agents, and/or compounds may also be utilized to treat specific diseases, including vulnerable plaque. Therapeutic agents may also be delivered to the region of a disease site. In regional delivery, liquid formulations may be desirable to increase the efficacy and deliverability of the particular drug. Also, the devices may be modified to promote endothelialization. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until delivered and positioned. In addition, the devices utilized to deliver the implantable medical devices may be modified to reduce the potential for damaging the implantable medical device during deployment. Medical devices include stents, grafts, anastomotic devices, perivascular wraps, sutures and staples. In addition, various polymer combinations may be utilized to control the elution rates of the therapeutic drugs, agents and/or compounds from the implantable medical devices.

L6 ANSWER 4 OF 59 USPATFULL on STN

ACCESSION NUMBER: 2005:267648 USPATFULL
TITLE: Use of antioxidants to prevent oxidation and reduce
drug degradation in drug eluting medical devices
INVENTOR(S): Fennimore, Roy R. JR., Titusville, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005232964	A1	20051020
APPLICATION INFO.:	US 2004-823834	A1	20040414 (10)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	PHILIP S. JOHNSON, JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003, US		
NUMBER OF CLAIMS:	35		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	52 Drawing Page(s)		
LINE COUNT:	6544		

AB Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological organism's reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and/or compounds may be utilized to promote healing, including the formation of blood clots. The drugs, agents, and/or compounds may also be utilized to treat specific diseases, including vulnerable plaque. Therapeutic agents may also be delivered to the region of a disease site. In regional delivery, liquid formulations may be desirable to increase the efficacy and deliverability of the particular drug. Also, the devices may be modified to promote endothelialization. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until delivered and positioned. In addition, the devices utilized to deliver the implantable medical devices may be modified to reduce the potential for damaging the implantable medical device during deployment. Medical devices include stents, grafts, anastomotic devices, perivascular wraps, sutures and staples. In addition, various polymer combinations may be utilized to control the elution rates of the therapeutic drugs, agents and/or compounds from the implantable medical devices. In each of these instances, antioxidants are utilized to prolong product integrity.

L6 ANSWER 5 OF 59 USPATFULL on STN

ACCESSION NUMBER: 2005:255693 USPATFULL
TITLE: Solution formulations of sirolimus and its analogs for
CAD treatment
INVENTOR(S): Falotico, Robert, Belle Mead, NJ, UNITED STATES
Zhao, Jonathon Z., Belle Mead, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005222191	A1	20051006
APPLICATION INFO.:	US 2004-813965	A1	20040331 (10)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	PHILIP S. JOHNSON, JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003, US		
NUMBER OF CLAIMS:	10		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	51 Drawing Page(s)		

LINE COUNT: 5953

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological organism's reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and/or compounds may be utilized to promote healing, including the formation of blood clots. Therapeutic agents may also be delivered to the region of a disease site. In regional delivery, liquid formulations may be desirable to increase the efficacy and deliverability of the particular drug. Also, the devices may be modified to promote endothelialization. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until delivered and positioned. In addition, the devices utilized to deliver the implantable medical devices may be modified to reduce the potential for damaging the implantable medical device during deployment. Medical devices include stents, grafts, anastomotic devices, perivascular wraps, sutures and staples. In addition, various polymer combinations may be utilized to control the elution rates of the therapeutic drugs, agents and/or compounds from the implantable medical devices.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 6 OF 59 USPATFULL on STN

ACCESSION NUMBER: 2005:254342 USPATFULL

TITLE: Drug delivery device

INVENTOR(S): Falotico, Robert, Belle Mead, NJ, UNITED STATES
Scheuble, Theresa, Rockaway, NJ, UNITED STATES
Kopia, Gregory Alan, Hillsborough, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005220836	A1	20051006
APPLICATION INFO.:	US 2004-813976	A1	20040331 (10).
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	PHILIP S. JOHNSON, JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003, US		
NUMBER OF CLAIMS:	8		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	51 Drawing Page(s)		
LINE COUNT:	5727		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological organism's reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and/or compounds may be utilized to promote healing, including the formation of blood clots. Therapeutic agents may also be delivered to the region of a disease site. Also, the devices may be modified to promote endothelialization. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the

medical device until delivered and positioned. In addition, the devices utilized to deliver the implantable medical devices may be modified to reduce the potential for damaging the implantable medical device during deployment. Medical devices include stents, grafts, anastomotic devices, perivascular wraps, sutures and staples. In addition, various polymer combinations may be utilized to control the elution rates of the therapeutic drugs, agents and/or compounds from the implantable medical devices.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 7 OF 59 USPATFULL on STN

ACCESSION NUMBER: 2005:241683 USPATFULL

TITLE: Local vascular delivery of Panzem in combination with rapamycin to prevent restenosis following vascular injury

INVENTOR(S): Falotico, Robert, Belle Mead, NJ, UNITED STATES
Parry, Tom Jay, Hellertown, PA, UNITED STATES
Zhao, Jonathon Z., Belle Mead, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005209688	A1	20050922
APPLICATION INFO.:	US 2004-805736	A1	20040322 (10)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	PHILIP S. JOHNSON, JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003, US		
NUMBER OF CLAIMS:	14		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	48 Drawing Page(s)		
LINE COUNT:	5347		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological organism's reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and/or compounds may be utilized to promote healing, including the formation of blood clots. Also, the devices may be modified to promote endothelialization. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until delivered and positioned. In addition, the devices utilized to deliver the implantable medical devices may be modified to reduce the potential for damaging the implantable medical device during deployment. Medical devices include stents, grafts, anastomotic devices, perivascular wraps, sutures and staples. In addition, various polymer combinations may be utilized to control the elution rates of the therapeutic drugs, agents and/or compounds from the implantable medical devices.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 8 OF 59 USPATFULL on STN

ACCESSION NUMBER: 2005:240092 USPATFULL

TITLE: Local vascular delivery of etoposide in combination with rapamycin to prevent restenosis following vascular injury

INVENTOR(S): Falotico, Robert, Belle Mead, NJ, UNITED STATES

Parry, Tom Jay, Hellertown, PA, UNITED STATES
Zhao, Jonathan Z., Belle Mead, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005208092	A1	20050922
APPLICATION INFO.:	US 2004-805722	A1	20040322 (10)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	PHILIP S. JOHNSON, JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003, US		
NUMBER OF CLAIMS:	22		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	42 Drawing Page(s)		
LINE COUNT:	5198		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological organism's reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and/or compounds may be utilized to promote healing, including the formation of blood clots. Also, the devices may be modified to promote endothelialization. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until delivered and positioned. In addition, the devices utilized to deliver the implantable medical devices may be modified to reduce the potential for damaging the implantable medical device during deployment. Medical devices include stents, grafts, anastomotic devices, perivascular wraps, sutures and staples. In addition, various polymer combinations may be utilized to control the elution rates of the therapeutic drugs, agents and/or compounds from the implantable medical devices.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 9 OF 59 USPATFULL on STN
ACCESSION NUMBER: 2005:233125 USPATFULL
TITLE: Local vascular delivery of topotecan in combination with rapamycin to prevent restenosis following vascular injury
INVENTOR(S): Falotico, Robert, Belle Mead, NJ, UNITED STATES
Parry, Tom Jay, Hellertown, PA, UNITED STATES
Zhao, Jonathon Z., Belle Mead, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005202059	A1	20050915
APPLICATION INFO.:	US 2004-796397	A1	20040309 (10)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	PHILIP S. JOHNSON, JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003, US		
NUMBER OF CLAIMS:	24		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	41 Drawing Page(s)		
LINE COUNT:	5096		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Medical devices, and in particular implantable medical devices, may be

coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological organism's reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and/or compounds may be utilized to promote healing, including the formation of blood clots. Also, the devices may be modified to promote endothelialization. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until delivered and positioned. In addition, the devices utilized to deliver the implantable medical devices may be modified to reduce the potential for damaging the implantable medical device during deployment. Medical devices include stents, grafts, anastomotic devices, perivascular wraps, sutures and staples. In addition, various polymer combinations may be utilized to control the elution rates of the therapeutic drugs, agents and/or compounds from the implantable medical devices.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 10 OF 59 USPATFULL on STN

ACCESSION NUMBER: 2005:215931 USPATFULL

TITLE: Radioprotective compound coating for medical devices

INVENTOR(S): O'Hara, Michael D., Columbia, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005187608	A1	20050825
APPLICATION INFO.:	US 2004-785519	A1	20040224 (10)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	PHILIP S. JOHNSON, JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003, US		
NUMBER OF CLAIMS:	14		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	33 Drawing Page(s)		
LINE COUNT:	4794		

AB Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological organism's reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and/or compounds may be utilized to promote healing, including the formation of blood clots. Also, the devices may be modified to promote endothelialization. Other compounds may include those that prevent damage from ionizing radiation. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until delivered and positioned. In addition, the devices utilized to deliver the implantable medical devices may be modified to reduce the potential for damaging the implantable medical device during deployment. Medical devices include stents, grafts, anastomotic devices, perivascular wraps, sutures and staples. In addition, various polymer combinations may be utilized to control the elution rates of the therapeutic drugs, agents and/or compounds from the implantable medical devices.

L6 ANSWER 11 OF 59 USPATFULL on STN

ACCESSION NUMBER: 2005:210000 USPATFULL
TITLE: Local vascular delivery of cladribine in combination
with rapamycin to prevent restenosis following vascular
injury
INVENTOR(S): Falotico, Robert, Belle Mead, NJ, UNITED STATES
Parry, Tom Jay, Hellertown, PA, UNITED STATES
Zhao, Jonathon Z., Belle Mead, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005182485	A1	20050818
APPLICATION INFO.:	US 2004-780596	A1	20040218 (10)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	PHILIP S. JOHNSON, JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003, US		
NUMBER OF CLAIMS:	14		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	40 Drawing Page(s)		
LINE COUNT:	4954		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological organism's reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and/or compounds may be utilized to promote healing, including the formation of blood clots. Also, the devices may be modified to promote endothelialization. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until delivered and positioned. In addition, the devices utilized to deliver the implantable medical devices may be modified to reduce the potential for damaging the implantable medical device during deployment. Medical devices include stents, grafts, anastomotic devices, perivascular wraps, sutures and staples. In addition, various polymer combinations may be utilized to control the elution rates of the therapeutic drugs, agents and/or compounds from the implantable medical devices.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 12 OF 59 USPATFULL on STN

ACCESSION NUMBER: 2005:190551 USPATFULL
TITLE: Implantable medical device
INVENTOR(S): Wang, Xingwu, Wellsville, NY, UNITED STATES
Greenwald, Howard J., Rochester, NY, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005165471	A1	20050728
APPLICATION INFO.:	US 2004-950148	A1	20040924 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2004-923579, filed on 20 Aug 2004, PENDING Continuation-in-part of Ser. No. US 2004-914691, filed on 9 Aug 2004, PENDING Continuation-in-part of Ser. No. US 2004-887521, filed on 7 Jul 2004, PENDING Continuation-in-part of Ser. No. US 2004-867517, filed on 14 Jun 2004, PENDING		

Continuation-in-part of Ser. No. US 2004-810916, filed on 26 Mar 2004, GRANTED, Pat. No. US 6846985
 Continuation-in-part of Ser. No. US 2004-808618, filed on 24 Mar 2004, PENDING Continuation-in-part of Ser. No. US 2004-786198, filed on 25 Feb 2004, PENDING Continuation-in-part of Ser. No. US 2004-780045, filed on 17 Feb 2004, PENDING Continuation-in-part of Ser. No. US 2003-747472, filed on 29 Dec 2003, PENDING Continuation-in-part of Ser. No. US 2003-744543, filed on 22 Dec 2003, PENDING Continuation-in-part of Ser. No. US 2003-442420, filed on 21 May 2003, PENDING Continuation-in-part of Ser. No. US 2003-409505, filed on 8 Apr 2003, GRANTED, Pat. No. US 6815609

DOCUMENT TYPE: Utility
 FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: HOWARD J. GREENWALD P.C., 349 W. COMMERCIAL STREET SUITE 2490, EAST ROCHESTER, NY, 14445-2408, US
 NUMBER OF CLAIMS: 35
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 19 Drawing Page(s)
 LINE COUNT: 5434

AB A metallic stent that, when it is contacted with an input alternating current electromagnetic field and a static magnetic field that contacts biological matter located within the stent, an output signal is produced that that has a fixed phase relationship with the input signal and that has a magnitude that is at least about 0.01 times as great as the magnitude of the input signal.

L6 ANSWER 13 OF 59 USPATFULL on STN

ACCESSION NUMBER: 2005:182977 USPATFULL
 TITLE: Local vascular delivery of mycophenolic acid in combination with rapamycin to prevent restenosis following vascular injury
 INVENTOR(S): Falotico, Robert, Belle Mead, NJ, UNITED STATES
 Parry, Tom Jay, Hellertown, PA, UNITED STATES
 Zhao, Jonathon Z., Belle Mead, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005158360	A1	20050721
APPLICATION INFO.:	US 2004-761032	A1	20040120 (10)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	PHILIP S. JOHNSON, JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003, US		
NUMBER OF CLAIMS:	9		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	33 Drawing Page(s)		
LINE COUNT:	4676		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological organism's reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and/or compounds may be utilized to promote healing, including the formation of blood clots. Also, the devices may be modified to promote endothelialization. Various materials and coating methodologies

may be utilized to maintain the drugs, agents or compounds on the medical device until delivered and positioned. In addition, the devices utilized to deliver the implantable medical devices may be modified to reduce the potential for damaging the implantable medical device during deployment. Medical devices include stents, grafts, anastomotic devices, perivascular wraps, sutures and staples. In addition, various polymer combinations may be utilized to control the elution rates of the therapeutic drugs, agents and/or compounds from the implantable medical devices.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 14 OF 59 USPATFULL on STN

ACCESSION NUMBER: 2005:172420 USPATFULL
 TITLE: Implantable medical device
 INVENTOR(S): Wang, Xingwu, Wellsville, NY, UNITED STATES
 Greenwald, Howard J., Rochester, NY, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005149169	A1	20050707
APPLICATION INFO.:	US 2004-974412	A1	20041027 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2004-950148, filed on 24 Sep 2004, PENDING Continuation-in-part of Ser. No. US 2004-923579, filed on 20 Aug 2004, PENDING Continuation-in-part of Ser. No. US 2004-914691, filed on 9 Aug 2004, PENDING Continuation-in-part of Ser. No. US 2004-887521, filed on 7 Jul 2004, PENDING Continuation-in-part of Ser. No. US 2004-867517, filed on 14 Jun 2004, PENDING Continuation-in-part of Ser. No. US 2004-810916, filed on 26 Mar 2004, GRANTED, Pat. No. US 6846985 Continuation-in-part of Ser. No. US 2004-808618, filed on 24 Mar 2004, PENDING Continuation-in-part of Ser. No. US 2004-786198, filed on 25 Feb 2004, PENDING Continuation-in-part of Ser. No. US 2004-780045, filed on 17 Feb 2004, PENDING Continuation-in-part of Ser. No. US 2003-747472, filed on 29 Dec 2003, PENDING Continuation-in-part of Ser. No. US 2003-744543, filed on 22 Dec 2003, PENDING Continuation-in-part of Ser. No. US 2003-442420, filed on 21 May 2003, PENDING Continuation-in-part of Ser. No. US 2003-409505, filed on 8 Apr 2003, GRANTED, Pat. No. US 6815609		

DOCUMENT TYPE: Utility
 FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: HOWARD J. GREENWALD P.C., 349 W. COMMERCIAL STREET
 SUITE 2490, EAST ROCHESTER, NY, 14445-2408, US

NUMBER OF CLAIMS: 59
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 26 Drawing Page(s)
 LINE COUNT: 6156

AB An implantable medical device assembly that contains magnetic material with a saturation magnetization of at least about 0.15 Tesla and which has a direct current permeability at a static magnetic field value of 1.5 Tesla of at least 1.1. When the magnetic material and is simultaneously subjected to an alternating current electromagnetic field with a frequency of 64 megahertz and a static magnetic field of 1.5 Tesla, it has a magnetization of less than 100 electromagnetic units per cubic centimeter.

L6 ANSWER 15 OF 59 USPATFULL on STN

ACCESSION NUMBER: 2005:159467 USPATFULL

TITLE: Endovascular graft with differentiable porosity along
its length
INVENTOR(S): Rush, Scott Lyle, Coral Springs, FL, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005137677	A1	20050623
APPLICATION INFO.:	US 2003-737983	A1	20031217 (10)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	PHILIP S. JOHNSON, JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003, US		
NUMBER OF CLAIMS:	26		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	26 Drawing Page(s)		
LINE COUNT:	3551		

AB Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device such as a stent-graft. These therapeutic drugs, agents or compounds may also further reduce a biological organism's reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and/or compounds may be utilized to promote healing, including the formation of blood clots. A stent-graft fabricated from a thin-walled, high strength material provides for a more durable and lower profile endoprosthesis. The stent-graft comprises one or more stent segments covered with a fabric formed by the weaving, knitting or braiding of a biocompatible, high tensile strength, abrasion resistant, highly durable yarn such as ultra high molecular weight polyethylene. The one or more stent segments may be balloon expandable or self-expanding. The fabric may be attached to the stent segments utilizing any number of known materials and techniques. In addition, the pore size of the graft material may be varied.

L6 ANSWER 16 OF 59 USPATFULL on STN

ACCESSION NUMBER: 2005:157882 USPATFULL
TITLE: Local vascular delivery of trichostatin a alone or in
combination with sirolimus to prevent restenosis
following vascular injury
INVENTOR(S): Falotico, Robert, Belle Mead, NJ, UNITED STATES
Parry, Tom Jay, Hellertown, PA, UNITED STATES
Zhao, Jonathon Zhong, Belle Mead, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005136090	A1	20050623
APPLICATION INFO.:	US 2003-742346	A1	20031219 (10)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	PHILIP S. JOHNSON, JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003, US		
NUMBER OF CLAIMS:	14		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	28 Drawing Page(s)		
LINE COUNT:	4522		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The

medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological organism's reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and/or compounds may be utilized to promote healing, including the formation of blood clots. Also, the devices may be modified to promote endothelialization. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until delivered and positioned. In addition, the devices utilized to deliver the implantable medical devices may be modified to reduce the potential for damaging the implantable medical device during deployment. Medical devices include stents, grafts, anastomotic devices, perivascular wraps, sutures and staples. In addition, various polymer combinations may be utilized to control the elution rates of the therapeutic drugs, agents and/or compounds from the implantable medical devices.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 17 OF 59 USPATFULL on STN

ACCESSION NUMBER: 2005:125479 USPATFULL

TITLE: Medical device with multiple coating layers

INVENTOR(S): Wang, Xingwu, Wellsville, NY, UNITED STATES
Greenwald, Howard J., Rochester, NY, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005107870	A1	20050519
APPLICATION INFO.:	US 2004-923579	A1	20040820 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2004-914691, filed on 9 Aug 2004, PENDING Continuation-in-part of Ser. No. US 2004-887521, filed on 7 Jul 2004, PENDING Continuation-in-part of Ser. No. US 2004-867517, filed on 14 Jun 2004, PENDING Continuation-in-part of Ser. No. US 2004-810916, filed on 26 Mar 2004, GRANTED, Pat. No. US 6846985 Continuation-in-part of Ser. No. US 2004-808618, filed on 24 Mar 2004, PENDING Continuation-in-part of Ser. No. US 2004-786198, filed on 25 Feb 2004, PENDING Continuation-in-part of Ser. No. US 2004-780045, filed on 17 Feb 2004, PENDING Continuation-in-part of Ser. No. US 2003-747472, filed on 29 Dec 2003, PENDING Continuation-in-part of Ser. No. US 2003-744543, filed on 22 Dec 2003, PENDING Continuation-in-part of Ser. No. US 2003-442420, filed on 21 May 2003, PENDING Continuation-in-part of Ser. No. US 2003-409505, filed on 8 Apr 2003, GRANTED, Pat. No. US 6815609		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	HOWARD J. GREENWALD P.C., 349 W. COMMERCIAL STREET SUITE 2490, EAST ROCHESTER, NY, 14445-2408, US		
NUMBER OF CLAIMS:	62		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	54 Drawing Page(s)		
LINE COUNT:	18628		

AB An implantable medical device that contains two coating layers disposed above at least one of its surfaces. The first coating layer contains a biologically active material; and the second coating layer contains a polymeric material and nanomagnetic material disposed on the first coating layer; the second coating layer is substantially free of the biologically active material. The nanomagnetic material has a saturation

magnetization of from about 2 to about 3000 electromagnetic units per cubic centimeter, and it contains nanomagnetic particles with an average particle size of less than about 100 nanometers; the average coherence length between adjacent nanomagnetic particles is less than 100 nanometers.

L6 ANSWER 18 OF 59 USPATFULL on STN

ACCESSION NUMBER: 2005:92457 USPATFULL
 TITLE: Medical device with low magnetic susceptibility
 INVENTOR(S): Wang, Xingwu, Wellsville, NY, UNITED STATES
 Greenwald, Howard J., Rochester, NY, UNITED STATES
 Gunderman, Robert D., Honeyoye Falls, NY, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005079132	A1	20050414
APPLICATION INFO.:	US 2004-914691	A1	20040809 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2004-887521, filed on 7 Jul 2004, PENDING Continuation-in-part of Ser. No. US 2004-867517, filed on 14 Jun 2004, PENDING Continuation-in-part of Ser. No. US 2004-810916, filed on 26 Mar 2004, GRANTED, Pat. No. US 6846985 Continuation-in-part of Ser. No. US 2004-808618, filed on 24 Mar 2004, PENDING Continuation-in-part of Ser. No. US 2004-786198, filed on 25 Feb 2004, PENDING Continuation-in-part of Ser. No. US 2004-780045, filed on 17 Feb 2004, PENDING Continuation-in-part of Ser. No. US 2003-747472, filed on 29 Dec 2003, PENDING Continuation-in-part of Ser. No. US 2003-744543, filed on 22 Dec 2003, PENDING Continuation-in-part of Ser. No. US 2003-442420, filed on 21 May 2003, PENDING Continuation-in-part of Ser. No. US 2003-409505, filed on 8 Apr 2003, GRANTED, Pat. No. US 6815609		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	HOWARD J. GREENWALD P.C., 349 W. COMMERCIAL STREET SUITE 2490, EAST ROCHESTER, NY, 14445-2408, US		
NUMBER OF CLAIMS:	127		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	52 Drawing Page(s)		
LINE COUNT:	17912		

AB An assembly with a substrate, nanomagnetic material and magetoresistive material. The nanomagnetic material has a saturation magnetization of from about 2 to about 3000 electromagnetic units per cubic centimeter; and it contains nanomagnetic particles with an average particle size of less than about 100 nanometers. The average coherence length between adjacent nanomagnetic particles is less than 100 nanometers.

L6 ANSWER 19 OF 59 USPATFULL on STN

ACCESSION NUMBER: 2005:38736 USPATFULL
 TITLE: Coating for controlled release of a therapeutic agent
 INVENTOR(S): Borges, John, Miami Lakes, FL, UNITED STATES
 Carballo, Maritza, Miramar, FL, UNITED STATES
 Narayanan, Pallassana V., Belle Mead, NJ, UNITED STATES
 Shaw, William D., JR., Plantation, FL, UNITED STATES
 Widenhouse, Christopher W., Pembroke Pines, FL, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005033417	A1	20050210

APPLICATION INFO.: US 2004-883328 A1 20040701 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-491646P	20030731 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PHILIP S. JOHNSON, JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003	
NUMBER OF CLAIMS:	4	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	27 Drawing Page(s)	
LINE COUNT:	4013	

AB Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological organism's reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and/or compounds may be utilized to promote healing, including the formation of blood clots. Also, the devices may be modified to promote endothelialization. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until delivered and positioned. In addition, the devices utilized to deliver the implantable medical devices may be modified to reduce the potential for damaging the implantable medical device during deployment. Medical devices include stents, grafts, anastomotic devices, perivascular wraps, sutures and staples. In addition, various polymer combinations may be utilized to control the elution rates of the therapeutic drugs, agents and/or compounds from the implantable medical devices.

L6 ANSWER 20 OF 59 USPATFULL on STN

ACCESSION NUMBER: 2005:30367 USPATFULL
TITLE: Medical device with low magnetic susceptibility
INVENTOR(S): Wang, Xingwu, Wellsville, NY, UNITED STATES
Greenwald, Howard Jay, Rochester, NY, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005025797	A1	20050203
APPLICATION INFO.:	US 2004-887521	A1	20040707 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2004-867517, filed on 14 Jun 2004, PENDING Continuation-in-part of Ser. No. US 2004-810916, filed on 26 Mar 2004, PENDING Continuation-in-part of Ser. No. US 2004-808618, filed on 24 Mar 2004, PENDING Continuation-in-part of Ser. No. US 2004-786198, filed on 25 Feb 2004, PENDING Continuation-in-part of Ser. No. US 2004-780045, filed on 17 Feb 2004, PENDING Continuation-in-part of Ser. No. US 2003-747472, filed on 29 Dec 2003, PENDING Continuation-in-part of Ser. No. US 2003-744543, filed on 22 Dec 2003, PENDING Continuation-in-part of Ser. No. US 2003-442420, filed on 21 May 2003, PENDING Continuation-in-part of Ser. No. US 2003-409505, filed on 8 Apr 2003, GRANTED, Pat. No. US 6815609		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	HOWARD J. GREENWALD P.C., 349 W. COMMERCIAL STREET		

SUITE 2490, EAST ROCHESTER, NY, 14445-2408

NUMBER OF CLAIMS: 137

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 42 Drawing Page(s)

LINE COUNT: 17461

AB An assembly that contains a medical device and biological material within which the medical device is disposed. The assembly has a magnetic susceptibility within the range of plus or minus 1+10.sup.-3 centimeter-gram-seconds

L6 ANSWER 21 OF 59 USPATFULL on STN

ACCESSION NUMBER: 2005:5555 USPATFULL

TITLE: Heparin barrier coating for controlled drug release

INVENTOR(S): Llanos, Gerard H., Stewartsville, NJ, UNITED STATES

Narayanan, Pallassana V., Belle Mead, NJ, UNITED STATES

Papandreou, George, Bridgewater, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005004663	A1	20050106
APPLICATION INFO.:	US 2004-872990	A1	20040621 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-850482, filed on 7 May 2001, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	PHILIP S. JOHNSON, JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003		
NUMBER OF CLAIMS:	6		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	53 Drawing Page(s)		
LINE COUNT:	6606		

AB Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological organism's reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and/or compounds may be utilized to promote healing, including the formation of blood clots. The drugs, agents, and/or compounds may also be utilized to treat specific diseases, including vulnerable plaque. Therapeutic agents may also be delivered to the region of a disease site. In regional delivery, liquid formulations may be desirable to increase the efficacy and deliverability of the particular drug. Also, the devices may be modified to promote endothelialization. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until delivered and positioned. In addition, the devices utilized to deliver the implantable medical devices may be modified to reduce the potential for damaging the implantable medical device during deployment. Medical devices include stents, grafts, anastomotic devices, perivascular wraps, sutures and staples. In addition, various polymer combinations as well as other therapeutic agents may be utilized to control the elution rates of the therapeutic drugs, agents and/or compounds from the implantable medical devices. In each of these instances, antioxidants are utilized to prolong product integrity.

L6 ANSWER 22 OF 59 USPATFULL on STN

ACCESSION NUMBER: 2004:321764 USPATFULL

TITLE: Therapeutic assembly
 INVENTOR(S): Wang, Xingwu, Wellsville, NY, UNITED STATES
 Greenwald, Howard J., Rochester, NY, UNITED STATES
 Lanzafame, John, Victor, NY, UNITED STATES
 Weiner, Michael L., Webster, NY, UNITED STATES
 Connelly, Patrick R., Rochester, NY, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004254419	A1	20041216
APPLICATION INFO.:	US 2004-867517	A1	20040614 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2004-810916, filed on 26 Mar 2004, PENDING Continuation-in-part of Ser. No. US 2004-808618, filed on 24 Mar 2004, PENDING Continuation-in-part of Ser. No. US 2004-786198, filed on 25 Feb 2004, PENDING Continuation-in-part of Ser. No. US 2004-780045, filed on 17 Feb 2004, PENDING Continuation-in-part of Ser. No. US 2003-747472, filed on 29 Dec 2003, PENDING Continuation-in-part of Ser. No. US 2003-744543, filed on 22 Dec 2003, PENDING Continuation-in-part of Ser. No. US 2003-409505, filed on 8 Apr 2003, PENDING Continuation-in-part of Ser. No. US 2003-442420, filed on 21 May 2003, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	HOWARD J. GREENWALD P.C., 349 W. COMMERCIAL STREET SUITE 2490, EAST ROCHESTER, NY, 14445-2408		
NUMBER OF CLAIMS:	175		
EXEMPLARY CLAIM:	CLM-1-177		
NUMBER OF DRAWINGS:	40 Drawing Page(s)		
LINE COUNT:	16208		

AB A therapeutic assembly that contains a therapeutic agent, a cytotoxic radioactive material, and a nanomagnetic material with nanomagnetic particles. The nanomagnetic particles have an average particle size of less than about 100 nanometers; and the average coherence length between adjacent nanomagnetic particles is less than 100 nanometers. The nanomagnetic material has a saturation magnetization of from about 2 to about 3000 electromagnetic units per cubic centimeter, a phase transition temperature of from about 40 to about 200 degrees Celsius, and a saturation magnetization of from about 2 to about 3,000 electromagnetic units per cubic centimeter

L6 ANSWER 23 OF 59 USPATFULL on STN
 ACCESSION NUMBER: 2004:300546 USPATFULL
 TITLE: Increased biocompatibility of implantable medical devices
 INVENTOR(S): Falotico, Robert, Belle Mead, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004236416	A1	20041125
APPLICATION INFO.:	US 2004-848090	A1	20040518 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-471943P	20030520 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PHILIP S. JOHNSON, JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003	
NUMBER OF CLAIMS:	6	
EXEMPLARY CLAIM:	1	

NUMBER OF DRAWINGS: 25 Drawing Page(s)

LINE COUNT: 3721

AB Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological organism's reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and/or compounds may be utilized to promote healing, including the formation of blood clots. Also, the devices may be modified to promote endothelialization. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until delivered and positioned. In addition, the devices utilized to deliver the implantable medical devices may be modified to reduce the potential for damaging the implantable medical device during deployment. Medical devices include stents, grafts, anastomotic devices, perivascular wraps, sutures and staples.

L6 ANSWER 24 OF 59 USPATFULL on STN

ACCESSION NUMBER: 2004:268745 USPATFULL

TITLE: Novel nanomagnetic particles

INVENTOR(S): Wang, Xingwu, Wellsville, NY, UNITED STATES
Greenwald, Howard J., Rochester, NY, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004210289	A1	20041021
APPLICATION INFO.:	US 2004-808618	A1	20040324 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2003-366082, filed on 13 Feb 2003, PENDING Continuation-in-part of Ser. No. US 2002-324773, filed on 18 Dec 2002, PENDING Continuation-in-part of Ser. No. US 2002-90553, filed on 4 Mar 2002, PENDING Continuation-in-part of Ser. No. US 2002-229183, filed on 26 Aug 2002, PENDING Continuation-in-part of Ser. No. US 2002-242969, filed on 13 Sep 2002, PENDING Continuation-in-part of Ser. No. US 2002-260247, filed on 30 Sep 2002, GRANTED, Pat. No. US 6673999 Continuation-in-part of Ser. No. US 2002-273738, filed on 18 Oct 2002, PENDING Continuation-in-part of Ser. No. US 2002-303264, filed on 25 Nov 2002, GRANTED, Pat. No. US 6713671 Continuation-in-part of Ser. No. US 2002-313847, filed on 7 Dec 2002, PENDING Continuation-in-part of Ser. No. US 2002-303264, filed on 25 Nov 2002, GRANTED, Pat. No. US 6713671		

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: HOWARD J. GREENWALD P.C., 349 W. COMMERCIAL STREET
SUITE 2490, EAST ROCHESTER, NY, 14445-2408

NUMBER OF CLAIMS: 98

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 51 Drawing Page(s)

LINE COUNT: 11684

AB A composition containing nanomagnetic particles. The, nanomagnetic particles have an average particle size of less than about 100 nanometers, a saturation magnetization of from about 2 to about 2,000 electromagnetic units per cubic centimeter, a phase transition temperature of from about 40 to about 200 degrees Celsius, and a squareness of from about 0.05 to about 1.0; the average coherence length

between adjacent nanomagnetic particles is less than about 100 nanometers; and the nanomagnetic particles are at least triatomic.

L6 ANSWER 25 OF 59 USPATFULL on STN

ACCESSION NUMBER: 2004:248574 USPATFULL
TITLE: Modified delivery device for coated medical devices
INVENTOR(S): Houghton, Michael J., Newark, DE, UNITED STATES
Majercak, David C., Stewartsville, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004193177	A1	20040930
APPLICATION INFO.:	US 2003-403195	A1	20030331 (10)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	PHILIP S. JOHNSON, JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003		
NUMBER OF CLAIMS:	14		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	25 Drawing Page(s)		
LINE COUNT:	3705		

AB Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological organism's reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and/or compounds may be utilized to promote healing, including the formation of blood clots. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until delivered and positioned. In addition, the devices utilized to deliver the implantable medical devices may be modified to reduce the potential for damaging the implantable medical device during deployment. Medical devices include stents, grafts, anastomotic devices, perivascular wraps, sutures and staples.

L6 ANSWER 26 OF 59 USPATFULL on STN

ACCESSION NUMBER: 2004:216463 USPATFULL
TITLE: Coated medical devices
INVENTOR(S): Roth, Noah M., Highland Park, NJ, UNITED STATES
Rush, Scott Lyle, Coral Springs, FL, UNITED STATES
Scheuble, Theresa, Rockaway, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004167572	A1	20040826
APPLICATION INFO.:	US 2003-371925	A1	20030220 (10)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	PHILIP S. JOHNSON, JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003		
NUMBER OF CLAIMS:	17		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	19 Drawing Page(s)		
LINE COUNT:	2938		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's

reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological organism's reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and/or compounds may be utilized to promote healing, including the formation of blood clots. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until delivered and positioned. Medical devices include stents, grafts, anastomotic devices, perivascular wraps, sutures and staples.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 27 OF 59 USPATFULL on STN

ACCESSION NUMBER: 2004:191235 USPATFULL

TITLE: Coated endovascular AAA device

INVENTOR(S): Rush, Scott Lyle, Coral Springs, FL, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004148010	A1	20040729
	US 6852122	B2	20050208
APPLICATION INFO.:	US 2003-349776	A1	20030123 (10)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	PHILIP S. JOHNSON, JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003		
NUMBER OF CLAIMS:	37		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	17 Drawing Page(s)		
LINE COUNT:	2899		

AB Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological organism's reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and/or compounds may be utilized to promote healing, including the formation of blood clots. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until delivered and positioned.

L6 ANSWER 28 OF 59 USPATFULL on STN

ACCESSION NUMBER: 2004:134221 USPATFULL

TITLE: Medical devices, drug coatings and methods for maintaining the drug coatings thereon

INVENTOR(S): Davila, Luis A., Coral Springs, FL, UNITED STATES
 Lentz, David Christian, Weston, FL, UNITED STATES
 Llanos, Gerard H., Stewartsville, NJ, UNITED STATES
 Mendez, Jorge Orlando, Miami, FL, UNITED STATES
 Narayanan, Pallassana V., Belle Mead, NJ, UNITED STATES
 Pelton, Alan Roy, Fremont, CA, UNITED STATES
 Roller, Mark B., North Brunswick, NJ, UNITED STATES
 Scheidt, Karl K., Pembroke Pines, FL, UNITED STATES
 Scopelianos, Angelo George, Whitehouse Station, NJ, UNITED STATES

Shaw, William Douglas, JR., Miami, FL, UNITED STATES
Silver, James H., Palo Alto, CA, UNITED STATES
Spaltro, John, Asbury, NJ, UNITED STATES
Trepanier, Christine, Union City, CA, UNITED STATES
Wilson, David J., Branchburg, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004102758	A1	20040527
APPLICATION INFO.:	US 2003-636435	A1	20030807 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-962496, filed on 25 Sep 2001, ABANDONED Continuation-in-part of Ser. No. US 2001-887464, filed on 22 Jun 2001, PENDING Continuation-in-part of Ser. No. US 2000-675882, filed on 29 Sep 2000, ABANDONED Continuation-in-part of Ser. No. US 2001-884729, filed on 19 Jun 2001, PENDING Continuation-in-part of Ser. No. US 2001-850482, filed on 7 May 2001, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	PHILIP S. JOHNSON, JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003		
NUMBER OF CLAIMS:	2		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	19 Drawing Page(s)		
LINE COUNT:	2319		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

AB Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological organism's reaction to the introduction of the medical device to the organism. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until delivered and positioned.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 29 OF 59 USPATFULL on STN
ACCESSION NUMBER: 2003:289405 USPATFULL
TITLE: Coated vascular devices
INVENTOR(S): Bosma, Gjalt, Opeinde, NETHERLANDS
van der Meulen, De heer Joost, Bergum, NETHERLANDS

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003204168	A1	20031030
APPLICATION INFO.:	US 2002-208581	A1	20020730 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2002-136569, filed on 30 Apr 2002, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	AUDLEY A. CIAMPORCERO JR., JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003		
NUMBER OF CLAIMS:	33		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	23 Drawing Page(s)		
LINE COUNT:	3252		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

AB Medical devices, and in particular implantable medical devices, may be

coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological organism's reaction to the introduction of the medical device to the organism. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until delivered and positioned.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 30 OF 59 USPATFULL on STN

ACCESSION NUMBER: 2003:94014 USPATFULL

TITLE: Coated medical devices

INVENTOR(S): Davila, Luis A., Pleasanton, CA, UNITED STATES
Wilson, David J., Branchburg, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003065377	A1	20030403
APPLICATION INFO.:	US 2002-136569	A1	20020430 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-966447, filed on 28 Sep 2001, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	AUDLEY A. CIAMPORCERO JR., JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003		
NUMBER OF CLAIMS:	65		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	17 Drawing Page(s)		
LINE COUNT:	2955		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological organism's reaction to the introduction of the medical device to the organism. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until delivered and positioned.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 31 OF 59 USPATFULL on STN

ACCESSION NUMBER: 2003:93983 USPATFULL

TITLE: Drug releasing anastomosis devices and methods for treating anastomotic sites

INVENTOR(S): Evens, Carl J., Branchburg, NJ, UNITED STATES
Weedock, Kevin, Princeton, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003065346	A1	20030403
APPLICATION INFO.:	US 2002-274782	A1	20021021 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-966447, filed on 28 Sep 2001, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		

LEGAL REPRESENTATIVE: AUDLEY A. CIAMPORCERO JR., JOHNSON & JOHNSON, ONE
JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003
NUMBER OF CLAIMS: 44
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 24 Drawing Page(s)
LINE COUNT: 3454

AB Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological organism's reaction to the introduction of the medical device to the organism. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until delivered and positioned.

L6 ANSWER 32 OF 59 USPATFULL on STN
ACCESSION NUMBER: 2003:93982 USPATFULL
TITLE: Anastomosis devices and methods for treating
anastomotic sites
INVENTOR(S): Weadock, Kevin, Princeton, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003065345	A1	20030403
APPLICATION INFO.:	US 2002-274770	A1	20021021 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-966447, filed on 28 Sep 2001, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	AUDLEY A. CIAMPORCERO JR., JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003		
NUMBER OF CLAIMS:	56		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	24 Drawing Page(s)		
LINE COUNT:	3485		

AB Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological organism's reaction to the introduction of the medical device to the organism. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until delivered and positioned.

L6 ANSWER 33 OF 59 USPATFULL on STN
ACCESSION NUMBER: 2003:87268 USPATFULL
TITLE: Coated medical devices for the treatment of vascular disease
INVENTOR(S): Falotico, Robert, Belle Mead, NJ, UNITED STATES
Spaltro, John, Asbury, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003060877	A1	20030327
APPLICATION INFO.:	US 2002-122978	A1	20020415 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-962496, filed on 25 Sep 2001, PENDING
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: AUDLEY A. CIAMPORCERO JR., JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003
NUMBER OF CLAIMS: 61
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 20 Drawing Page(s)
LINE COUNT: 2858

AB Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. In addition to reducing or substantially eliminating a biological organism's reaction to the introduction of the medical device to the organism, the medical device in combination with one or more therapeutic drugs, agents and/or compounds may be utilized to treat various vascular diseases, for example, restenosis and vulnerable plaque. In the case of vulnerable plaque, one or more drugs, agents or compounds may be utilized to treat the various aspects of vulnerable plaque and these drugs, agents and/or compounds may be released with a given release profile for the most effective treatment. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until delivered and positioned.

L6 ANSWER 34 OF 59 USPTFULL on STN

ACCESSION NUMBER: 2002:243987 USPTFULL
TITLE: Coated medical devices
INVENTOR(S): Lentz, David Christian, Weston, FL, UNITED STATES
Llanos, Gerard H., Stewartsville, NJ, UNITED STATES
Roller, Mark B., North Brunswick, NJ, UNITED STATES
Scopelianos, Angelo, Whitehouse Station, NJ, UNITED STATES
Weadock, Kevin, Princeton, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002133183	A1	20020919
APPLICATION INFO.:	US 2001-966447	A1	20010928 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-887464, filed on 22 Jun 2001, PENDING Continuation-in-part of Ser. No. US 2000-675882, filed on 29 Sep 2000, PENDING Continuation-in-part of Ser. No. US 2001-850482, filed on 7 May 2001, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	AUDLEY A. CIAMPORCERO JR., JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003		
NUMBER OF CLAIMS:	34		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	12 Drawing Page(s)		
LINE COUNT:	2304		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the

biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological organism's reaction to the introduction of the medical device to the organism. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until delivered and positioned.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 35 OF 59 USPATFULL on STN

ACCESSION NUMBER: 2002:206886 USPATFULL

TITLE: Medical devices, drug coatings and methods for maintaining the drug coatings thereon

INVENTOR(S): Davila, Luis A., Pleasanton, CA, UNITED STATES
Lentz, David Christian, Weston, FL, UNITED STATES
Llanos, Gerard H., Stewartsville, NJ, UNITED STATES
Mendez, Jorge Orlando, Miami, FL, UNITED STATES
Narayanan, Pallassana V., Belle Mead, NJ, UNITED STATES
Pelton, Alan Roy, Fremont, CA, UNITED STATES
Roller, Mark B., North Brunswick, NJ, UNITED STATES
Scheidt, Karl K., Pembroke Pines, FL, UNITED STATES
Scopelianos, Angelo George, Whitehouse Station, NJ, UNITED STATES
Shaw, William Douglas, JR., Miami, FL, UNITED STATES
Silver, James H., Redwood City, CA, UNITED STATES
Spaltro, John, Asbury, NJ, UNITED STATES
Trepanier, Christine, Fremont, CA, UNITED STATES
Wilson, David J., Ft. Lauderdale, FL, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002111590	A1	20020815
APPLICATION INFO.:	US 2001-962496	A1	20010925 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-887464, filed on 22 Jun 2001, PENDING Continuation-in-part of Ser. No. US 2000-675882, filed on 29 Sep 2000, PENDING Continuation-in-part of Ser. No. US 2001-884729, filed on 19 Jun 2001, PENDING Continuation-in-part of Ser. No. US 2001-850482, filed on 7 May 2001, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	AUDLEY A. CIAMPORCERO JR., JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003		
NUMBER OF CLAIMS:	99		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	19 Drawing Page(s)		
LINE COUNT:	2797		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological organism's reaction to the introduction of the medical device to the organism. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until delivered and positioned.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 36 OF 59 USPATFULL on STN

ACCESSION NUMBER: 2002:98835 USPATFULL
TITLE: Coated medical devices and sterilization thereof
INVENTOR(S): Bodnar, Stanko, Whitehouse Station, NJ, UNITED STATES
Llanos, Gerard H., Stewartsville, NJ, UNITED STATES
Roller, Mark B., North Brunswick, NJ, UNITED STATES
Scopelianos, Angelo, Whitehouse Station, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002051730	A1	20020502
APPLICATION INFO.:	US 2001-966783	A1	20010928 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-675882, filed on 29 Sep 2000, PENDING Continuation-in-part of Ser. No. US 2001-850482, filed on 7 May 2001, PENDING Continuation-in-part of Ser. No. US 2001-887464, filed on 22 Jun 2001, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	AUDLEY A. CIAMPORCERO JR., JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003		
NUMBER OF CLAIMS:	40		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	19 Drawing Page(s)		
LINE COUNT:	2703		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological organism's reaction to the introduction of the medical device to the organism. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until delivered and positioned. An efficient and effective sterilization process is also set forth.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 37 OF 59 EPFULL COPYRIGHT 2005 EPO/FIZ KA on STN

ACCESSION NUMBER: 2005:21287 EPFULL
ENTRY DATE PATENT: 20051102
ENTRY DATE PUBLICATION: 20051102
UPDATE DATE PUBLICAT.: 20051102
DATA UPDATE DATE: 20051102
DATA UPDATE WEEK: 200544
TITLE (ENGLISH): Solution formulations of sirolimus and its analogs for CAD treatment
TITLE (FRENCH): Formulations en solution de sirolimus et ses analogues pour le traitement de la coronaropathie
TITLE (GERMAN): Formulierungen von Sirolimus und seine Analoge in Loesungsform zur Behandlung von koronaren Herzkrankheit
INVENTOR(S): Falotico, Robert, 40 Black Horse Run, Belle Mead, NJ 08502, US; Zhao, Jonathon Z., 12 Briar Hill Court, Belle Mead, NJ 08502, US
PATENT APPLICANT(S): Cordis Corporation, 14201 N.W. 60th Avenue, Miami Lakes, Florida 33014, US
PATENT APPL. NUMBER: 280674
AGENT: Mercer, Christopher Paul, et al, Carpmiels & Ransford, 43-45 Bloomsbury Square, London WC1A 2RA, GB

AGENT NUMBER: 46612
 LANGUAGE OF FILING: English
 LANGUAGE OF PUBL.: English
 LANGUAGE OF PROCEDURE: English
 LANGUAGE OF TITLE: German; English; French
 DOCUMENT TYPE: Patent
 PATENT INFO TYPE: EPA2 Application published without search report
 PATENT INFORMATION:

	NUMBER	KIND	DATE
	EP 1591108	A2	20051102
DESIGNATED STATES:	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR		
EXTENSION STATES:	AL BA HR LV MK YU		
APPLICATION INFO.:	EP 2005-252016	A	20050331
PRIORITY INFO.:	US 2004-813965	A	20040331

ABEN

Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological organism's reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and/or compounds may be utilized to promote healing, including the formation of blood clots. Therapeutic agents may also be delivered to the region of a disease site. In regional delivery, liquid formulations may be desirable to increase the efficacy and deliverability of the particular drug. Also, the devices may be modified to promote endothelialization. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until delivered and positioned. In addition, the devices utilized to deliver the implantable medical devices may be modified to reduce the potential for damaging the implantable medical device during deployment. Medical devices include stents, grafts, anastomotic devices, perivascular wraps, sutures and staples. In addition, various polymer combinations may be utilized to control the elution rates of the therapeutic drugs, agents and/or compounds from the implantable medical devices.

L6 ANSWER 38 OF 59 EPFULL COPYRIGHT 2005 EPO/FIZ KA on STN

ACCESSION NUMBER: 2005:18814 EPFULL
 ENTRY DATE PATENT: 20051026
 ENTRY DATE PUBLICATION: 20051026
 UPDATE DATE PUBLICAT.: 20051026
 DATA UPDATE DATE: 20051026
 DATA UPDATE WEEK: 200543
 TITLE (ENGLISH): Local vascular delivery of 2-methoxyestradiol in combination with rapamycin to prevent restenosis following vascular injury
 TITLE (FRENCH): Administration vasculaire locale de 2-methoxyestradiol en combinaison avec Rapamycine pour la prevention de restenose a la suite d'une lesion vasculaire
 TITLE (GERMAN): Lokale, vaskulaere Verabreichung von 2-methoxyestradiol in Kombination mit Rapamycin zur Vorbeugung von Restenose nach Gefaessverletzungen
 INVENTOR(S): Falotico, Robert, 40 Black Horse Run, Belle Mead, NJ 08502, US; Parry, Tom Jay, 1452 Bette Lane, Hellertown, PA 18055, US; Zhao, Jonathon Z., 12 Briar Hill Court, Belle Mead, NJ 08502, US
 PATENT APPLICANT(S): Cordis Corporation, 14201 N.W. 60th Avenue, Miami

PATENT APPL. NUMBER: 280674
 AGENT: Mercer, Christopher Paul, et al, Carpmaels & Ransford,
 43-45 Bloomsbury Square, London WC1A 2RA, GB
 AGENT NUMBER: 46612
 LANGUAGE OF FILING: English
 LANGUAGE OF PUBL.: English
 LANGUAGE OF PROCEDURE: English
 LANGUAGE OF TITLE: German; English; French
 DOCUMENT TYPE: Patent
 PATENT INFO TYPE: EPA1 Application published with search report
 PATENT INFORMATION:

	NUMBER	KIND	DATE
	EP 1588725	A1	20051026
DESIGNATED STATES:	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT		
	LI LT LU MC NL PL PT RO SE SI SK TR		
EXTENSION STATES:	AL BA HR LV MK YU		
APPLICATION INFO.:	EP 2005-251712	A	20050321
PRIORITY INFO.:	US 2004-805736	A	20040322

ABEN

Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological organism's reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and/or compounds may be utilized to promote healing, including the formation of blood clots. Also, the devices may be modified to promote endothelialization. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until delivered and positioned. In addition, the devices utilized to deliver the implantable medical devices may be modified to reduce the potential for damaging the implantable medical device during deployment. Medical devices include stents, grafts, anastomotic devices, perivascular wraps, sutures and staples. In addition, various polymer combinations may be utilized to control the elution rates of the therapeutic drugs, agents and/or compounds from the implantable medical devices.

(image, 0.1, abstract drawing)

L6 ANSWER 39 OF 59 EPFULL COPYRIGHT 2005 EPO/FIZ KA on STN

ACCESSION NUMBER: 2005:16321 EPFULL
 ENTRY DATE PATENT: 20051019
 ENTRY DATE PUBLICATION: 20051019
 UPDATE DATE PUBLICAT.: 20051019
 DATA UPDATE DATE: 20051019
 DATA UPDATE WEEK: 200542
 TITLE (ENGLISH): The use of antioxidants to prevent oxidation and reduce drug degradation in drug eluting medical devices
 TITLE (FRENCH): Utilisation d'antioxydants pour la prevention d'oxydation et la reduction de la degradation des principes actifs dans les articles medicaux liberant des principes actifs
 TITLE (GERMAN): Verwendung von Antioxidantien zur Verhinderung von Oxidation und zur Reduzierung von Wirkstoffzersetzung in wirkstoffhaltigen medizinischen Artikeln
 INVENTOR(S): Fennimore, Roy R. (Jr.), 272 Wash Cross-Penn Road,

PATENT APPLICANT(S): Titusville, NJ 08560, US
 Cordis Corporation, 14201 N.W. 60th Avenue, Miami
 Lakes, Florida 33014, US
 PATENT APPL. NUMBER: 280674
 AGENT: Mercer, Christopher Paul, et al, Carpmaels & Ransford,
 43-45 Bloomsbury Square, London WC1A 2RA, GB
 AGENT NUMBER: 46612
 LANGUAGE OF FILING: English
 LANGUAGE OF PUBL.: English
 LANGUAGE OF PROCEDURE: English
 LANGUAGE OF TITLE: German; English; French
 DOCUMENT TYPE: Patent
 PATENT INFO TYPE: EPA2 Application published without search report
 PATENT INFORMATION:

	NUMBER	KIND	DATE
	EP 1586338	A2	20051019
DESIGNATED STATES:	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT		
	LI LT LU MC NL PL PT RO SE SI SK TR		
EXTENSION STATES:	AL BA HR LV MK YU		
APPLICATION INFO.:	EP 2005-252322	A	20050414
PRIORITY INFO.:	US 2004-823834	A	20040414

ABEN

Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological organism's reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and/or compounds may be utilized to promote healing, including the formation of blood clots. The drugs, agents, and/or compounds may also be utilized to treat specific diseases, including vulnerable plaque. Therapeutic agents may also be delivered to the region of a disease site. In regional delivery, liquid formulations may be desirable to increase the efficacy and deliverability of the particular drug. Also, the devices may be modified to promote endothelialization. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until delivered and positioned. In addition, the devices utilized to deliver the implantable medical devices may be modified to reduce the potential for damaging the implantable medical device during deployment. Medical devices include stents, grafts, anastomotic devices, perivascular wraps, sutures and staples. In addition, various polymer combinations may be utilized to control the elution rates of the therapeutic drugs, agents and/or compounds from the implantable medical devices. In each of these instances, antioxidants are utilized to prolong product integrity.

L6 ANSWER 40 OF 59 EPFULL COPYRIGHT 2005 EPO/FIZ KA on STN

ACCESSION NUMBER: 2005:16320 EPFULL
 ENTRY DATE PATENT: 20051019
 ENTRY DATE PUBLICATION: 20051019
 UPDATE DATE PUBLICAT.: 20051019
 DATA UPDATE DATE: 20051019
 DATA UPDATE WEEK: 200542
 TITLE (ENGLISH): The local administration of a combination of rapamycin
 and 17 beta-estradiol for the treatment of vulnerable
 plaque
 TITLE (FRENCH): Administration locale d'une combinaison de rapamycine
 et 17 beta-estradiol pour le traitement de plaque

TITLE (GERMAN): vulnerable
 Lokale Verabreichung einer Kombination von Rapamycin
 und 17 beta-Estradiol zur Behandlung von vulnerabler
 Plaque
 INVENTOR(S): Falotico, Robert, 40 Black Horse Run, Belle Mead, NJ
 08502, US
 PATENT APPLICANT(S): Cordis Corporation, 14201 N.W. 60th Avenue, Miami
 Lakes, Florida 33014, US
 PATENT APPL. NUMBER: 280674
 AGENT: Mercer, Christopher Paul, et al, Carpmaels & Ransford,
 43-45 Bloomsbury Square, London WC1A 2RA, GB
 AGENT NUMBER: 46612
 LANGUAGE OF FILING: English
 LANGUAGE OF PUBL.: English
 LANGUAGE OF PROCEDURE: English
 LANGUAGE OF TITLE: German; English; French
 DOCUMENT TYPE: Patent
 PATENT INFO TYPE: EPA2 Application published without search report
 PATENT INFORMATION:

	NUMBER	KIND	DATE
	EP 1586337	A2	20051019
DESIGNATED STATES:	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR		
EXTENSION STATES:	AL BA HR LV MK YU		
APPLICATION INFO.:	EP 2005-252315	A	20050414
PRIORITY INFO.:	US 2004-826058	A	20040415

ABEN

Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological organism's reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and/or compounds may be utilized to promote healing, including the formation of blood clots. The drugs, agents, and/or compounds may also be utilized to treat specific diseases, including vulnerable plaque. Therapeutic agents may also be delivered to the region of a disease site. In regional delivery, liquid formulations may be desirable to increase the efficacy and deliverability of the particular drug. Also, the devices may be modified to promote endothelialization. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until delivered and positioned. In addition, the devices utilized to deliver the implantable medical devices may be modified to reduce the potential for damaging the implantable medical device during deployment. Medical devices include stents, grafts, anastomotic devices, perivascular wraps, sutures and staples. In addition, various polymer combinations may be utilized to control the elution rates of the therapeutic drugs, agents and/or compounds from the implantable medical devices.

L6 ANSWER 41 OF 59 EPFULL COPYRIGHT 2005 EPO/FIZ KA on STN

ACCESSION NUMBER: 2005:11540 EPFULL
 ENTRY DATE PATENT: 20051006
 ENTRY DATE PUBLICATION: 20051006
 UPDATE DATE PUBLICAT.: 20051006
 DATA UPDATE DATE: 20051005
 DATA UPDATE WEEK: 200540
 TITLE (ENGLISH): Drug delivery device

TITLE (FRENCH): Systeme d'administration de medicaments
 TITLE (GERMAN): Arzneimittelabgabevorrichtung
 INVENTOR(S): Falotico, Robert, 40 Black Horse Run, Belle Mead, NJ 08502, US; Scheuble, Theresa, 49 Stephen Place, Rockaway, NJ 07866, US; Kopia, Gregory Alan, 58 Longfield Drive, Hillsborough, NJ 08844, US
 PATENT APPLICANT(S): Cordis Corporation, 14201 N.W. 60th Avenue Miami Lakes,, Florida 33014, US
 PATENT APPL. NUMBER: 280674
 AGENT: Mercer, Christopher Paul, et al, Carpmaels & Ransford, 43-45 Bloomsbury Square, London WC1A 2RA, GB
 AGENT NUMBER: 46612
 LANGUAGE OF FILING: English
 LANGUAGE OF PUBL.: English
 LANGUAGE OF PROCEDURE: English
 LANGUAGE OF TITLE: German; English; French
 DOCUMENT TYPE: Patent
 PATENT INFO TYPE: EPA2 Application published without search report
 PATENT INFORMATION:

	NUMBER	KIND	DATE
	EP 1582225	A2	20051005
DESIGNATED STATES:	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR		
EXTENSION STATES:	AL BA HR LV MK YU		
APPLICATION INFO.:	EP 2005-252017	A	20050331
PRIORITY INFO.:	US 2004-813976	A	20040331

ABEN

Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological organism's reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and/or compounds may be utilized to promote healing, including the formation of blood clots. Therapeutic agents may also be delivered to the region of a disease site. Also, the devices may be modified to promote endothelialization. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until delivered and positioned. In addition, the devices utilized to deliver the implantable medical devices may be modified to reduce the potential for damaging the implantable medical device during deployment. Medical devices include stents, grafts, anastomotic devices, perivascular wraps, sutures and staples. In addition, various polymer combinations may be utilized to control the elution rates of the therapeutic drugs, agents and/or compounds from the implantable medical devices.

L6 ANSWER 42 OF 59 EPFULL COPYRIGHT 2005 EPO/FIZ KA on STN

ACCESSION NUMBER: 2005:9245 EPFULL
 ENTRY DATE PATENT: 20050928
 ENTRY DATE PUBLICATION: 20050928
 UPDATE DATE PUBLICAT.: 20050928
 DATA UPDATE DATE: 20050928
 DATA UPDATE WEEK: 200539
 TITLE (ENGLISH): Local vascular delivery of etoposide in combination with rapamycin to prevent restenosis following vascular injury
 TITLE (FRENCH): Administration vasculaire locale d'Etoposide en

combinaison avec Rapamycine pour la prevention de
 restenose a la suite d'une lesion vasculaire
 Lokale, vaskulaere Verabreichung von Etoposide in
 Kombination mit Rapamycin zur Vorbeugung von Restenose
 nach Gefaessverletzungen
 TITLE (GERMAN):
 INVENTOR(S): Falotico, Robert, 40 Black Horse Run, Belle Mead NJ
 08502, US; Parry, Tom Jay, 1452 Bette Lane,
 Hellertown PA 18055, US; Zhao, Jonathon Z, 12 Briar
 Hill Court, Belle Mead NJ 08502, US
 PATENT APPLICANT(S): Cordis Corporation, 14201 N.W. 60th Avenue Miami
 Lakes,, Florida 33014, US
 PATENT APPL. NUMBER: 280674
 AGENT: Mercer, Christopher Paul, et al, Carpmiels & Ransford,
 43-45 Bloomsbury Square, London WC1A 2RA, GB
 AGENT NUMBER: 46612
 LANGUAGE OF FILING: English
 LANGUAGE OF PUBL.: English
 LANGUAGE OF PROCEDURE: English
 LANGUAGE OF TITLE: German; English; French
 DOCUMENT TYPE: Patent
 PATENT INFO TYPE: EPat Application published with search report
 PATENT INFORMATION:

	NUMBER	KIND	DATE
	EP 1579877	A1	20050928
DESIGNATED STATES:	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT		
	LI LT LU MC NL PL PT RO SE SI SK TR		
EXTENSION STATES:	AL BA HR LV MK YU		
APPLICATION INFO.:	EP 2005-251710	A	20050321
PRIORITY INFO.:	US 2004-805722	A	20040322

ABEN

Medical devices, and in particular implantable medical devices, may be
 coated to minimize or substantially eliminate a biological organism's
 reaction to the introduction of the medical device to the organism. The
 medical devices may be coated with any number of biocompatible materials.
 Therapeutic drugs, agents or compounds may be mixed with the biocompatible
 materials and affixed to at least a portion of the medical device. These
 therapeutic drugs, agents or compounds may also further reduce a biological
 organism's reaction to the introduction of the medical device to the
 organism. In addition, these therapeutic drugs, agents and/or compounds may
 be utilized to promote healing, including the formation of blood clots. Also,
 the devices may be modified to promote endothelialization. Various materials
 and coating methodologies may be utilized to maintain the drugs, agents or
 compounds on the medical device until delivered and positioned. In addition,
 the devices utilized to deliver the implantable medical devices may be
 modified to reduce the potential for damaging the implantable medical device
 during deployment. Medical devices include stents, grafts, anastomotic
 devices, perivascular wraps, sutures and staples. In addition, various
 polymer combinations may be utilized to control the elution rates of the
 therapeutic drugs, agents and/or compounds from the implantable medical
 devices.

(image, 0.1, abstract drawing)

L6 ANSWER 43 OF 59 EPPFULL COPYRIGHT 2005 EPO/FIZ KA on STN

ACCESSION NUMBER: 2005:6195 EPPFULL
 ENTRY DATE PATENT: 20050914
 ENTRY DATE PUBLICATION: 20050914
 UPDATE DATE PUBLICAT.: 20050914
 DATA UPDATE DATE: 20050914
 DATA UPDATE WEEK: 200537

TITLE (ENGLISH): Implantable vascular device for delivery of topotecan
 in combination with rapamycin
 TITLE (FRENCH): Dispositif vasculaire implantable pour
 l'administration de topotecan en association avec la
 rapamycine
 TITLE (GERMAN): Implantierbare vaskulaere Vorrichtung zur Abgabe von
 Topotecan in Kombination mit Rapamycin
 INVENTOR(S): Falotico, Robert, 40 Black Horse Run, Belle Mead, NJ
 08502, US; Parry, Tom Jay, 1452 Bette Lane, Hellertown,
 PA 18055, US; Zhao, Jonathon Z., 12 Briar Hill Court,
 Belle Mead, NJ 08502, US
 PATENT APPLICANT(S): Cordis Corporation, 14201 N.W. 60th Avenue Miami
 Lakes,, Florida 33014, US
 PATENT APPL. NUMBER: 280674
 AGENT: Mercer, Christopher Paul, et al, Carpmiels & Ransford,
 43-45 Bloomsbury Square, London WC1A 2RA, GB
 AGENT NUMBER: 46612
 LANGUAGE OF FILING: English
 LANGUAGE OF PUBL.: English
 LANGUAGE OF PROCEDURE: English
 LANGUAGE OF TITLE: German; English; French
 DOCUMENT TYPE: Patent
 PATENT INFO TYPE: EPA2 Application published without search report
 PATENT INFORMATION:

	NUMBER	KIND	DATE
	EP 1574228	A2	20050914
DESIGNATED STATES:	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT		
	LI LT LU MC NL PL PT RO SE SI SK TR		
EXTENSION STATES:	AL BA HR LV MK YU		
APPLICATION INFO.:	EP 2005-251389	A	20050308
PRIORITY INFO.:	US 2004-796397	A	20040309

ABEN

Medical devices, and in particular implantable medical devices, may be
 coated to minimize or substantially eliminate a biological organism's
 reaction to the introduction of the medical device to the organism. The
 medical devices may be coated with any number of biocompatible materials.
 Therapeutic drugs, agents or compounds may be mixed with the biocompatible
 materials and affixed to at least a portion of the medical device. These
 therapeutic drugs, agents or compounds may also further reduce a biological
 organism's reaction to the introduction of the medical device to the
 organism. In addition, these therapeutic drugs, agents and/or compounds may
 be utilized to promote healing, including the formation of blood clots. Also,
 the devices may be modified to promote endothelialization. Various materials
 and coating methodologies may be utilized to maintain the drugs, agents or
 compounds on the medical device until delivered and positioned. In addition,
 the devices utilized to deliver the implantable medical devices may be
 modified to reduce the potential for damaging the implantable medical device
 during deployment. Medical devices include stents, grafts, anastomotic
 devices, perivascular wraps, sutures and staples. In addition, various
 polymer combinations may be utilized to control the elution rates of the
 therapeutic drugs, agents and/or compounds from the implantable medical
 devices.

L6 ANSWER 44 OF 59 EPFULL COPYRIGHT 2005 EPO/FIZ KA on STN

ACCESSION NUMBER: 2005:5469 EPFULL
 ENTRY DATE PATENT: 20050907
 ENTRY DATE PUBLICATION: 20050907
 UPDATE DATE PUBLICAT.: 20050907
 DATA UPDATE DATE: 20050907
 DATA UPDATE WEEK: 200536

TITLE (ENGLISH): Local vascular delivery of cladribine in combination with rapamycin to prevent restenosis following vascular injury

TITLE (FRENCH): Administration vasculaire locale de Cladribine en combinaison avec Rapamycine pour la prevention de restenose a la suite d'une lesion vasculaire

TITLE (GERMAN): Lokale, vaskulaere Verabreichung von Cladribin in Kombination mit Rapamycin zur Vorbeugung von Restenose nach Gefaessverletzungen

INVENTOR(S): Falotico, Robert, 40 Black Horse Run, Belle Mead, NJ 08502, US; Parry, Tom Jay, 1452 Bette Lane, Hellertown, PA 18055, US; Zhao, Jonathon Z., 12 Briar Hill Court, NJ 08502, US

PATENT APPLICANT(S): Cordis Corporation, 14201 N.W. 60th Avenue Miami Lakes,, Florida 33014, US

PATENT APPL. NUMBER: 280674

AGENT: Mercer, Christopher Paul, et al, Carpmiels & Ransford, 43-45 Bloomsbury Square, London WC1A 2RA, GB

AGENT NUMBER: 46612

LANGUAGE OF FILING: English

LANGUAGE OF PUBL.: English

LANGUAGE OF PROCEDURE: English

LANGUAGE OF TITLE: German; English; French

DOCUMENT TYPE: Patent

PATENT INFO TYPE: EPA1 Application published with search report

PATENT INFORMATION:

	NUMBER	KIND	DATE
	EP 1570871	A1	20050907
DESIGNATED STATES:	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR		
EXTENSION STATES:	AL BA HR LV MK YU		
APPLICATION INFO.:	EP 2005-250908	A	20050217
PRIORITY INFO.:	US 2004-780596	A	20040218

ABEN

Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological organism's reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and/or compounds may be utilized to promote healing, including the formation of blood clots. Also, the devices may be modified to promote endothelialization. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until delivered and positioned. In addition, the devices utilized to deliver the implantable medical devices may be modified to reduce the potential for damaging the implantable medical device during deployment. Medical devices include stents, grafts, anastomotic devices, perivascular wraps, sutures and staples. In addition, various polymer combinations may be utilized to control the elution rates of the therapeutic drugs, agents and/or compounds from the implantable medical devices.

L6 ANSWER 45 OF 59 EPFULL COPYRIGHT 2005 EPO/FIZ KA on STN

ACCESSION NUMBER: 2005:4715 EPFULL

ENTRY DATE PATENT: 20050831

ENTRY DATE PUBLICATION: 20050831

UPDATE DATE PUBLICAT.: 20050831

DATA UPDATE DATE: 20050831
 DATA UPDATE WEEK: 200535
 TITLE (ENGLISH): Radioprotective compound coating for medical devices
 TITLE (FRENCH): Revetement d'un radioprotecteur pour dispositifs
 medicaux
 TITLE (GERMAN): Beschichtung mit strahlenschuetzender Verbindung fuer
 medizinische Geraete
 INVENTOR(S): O'Hara, D. Michael, 6309 Young Buck Circle, Columbia,
 MD 21045, US
 PATENT APPLICANT(S): Cordis Corporation, 14201 N.W. 60th Avenue Miami
 Lakes,, Florida 33014, US
 PATENT APPL. NUMBER: 280674
 AGENT: Mercer, Christopher Paul, et al, Carpmaels & Ransford,
 43-45 Bloomsbury Square, London WC1A 2RA, GB
 AGENT NUMBER: 46612
 LANGUAGE OF FILING: English
 LANGUAGE OF PUBL.: English
 LANGUAGE OF PROCEDURE: English
 LANGUAGE OF TITLE: German; English; French
 DOCUMENT TYPE: Patent
 PATENT INFO TYPE: EPA2 Application published without search report
 PATENT INFORMATION:

	NUMBER	KIND	DATE
	EP 1568387	A2	20050831
DESIGNATED STATES:	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT		
	LI LT LU MC NL PL PT RO SE SI SK TR		
EXTENSION STATES:	AL BA HR LV MK YU		
APPLICATION INFO.:	EP 2005-251061	A	20050223
PRIORITY INFO.:	US 2004-785519	A	20040224

ABEN

Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological organism's reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and/or compounds may be utilized to promote healing, including the formation of blood clots. Also, the devices may be modified to promote endothelialization. Other compounds may include those that prevent damage from ionizing radiation. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until delivered and positioned. In addition, the devices utilized to deliver the implantable medical devices may be modified to reduce the potential for damaging the implantable medical device during deployment. Medical devices include stents, grafts, anastomotic devices, perivascular wraps, sutures and staples. In addition, various polymer combinations may be utilized to control the elution rates of the therapeutic drugs, agents and/or compounds from the implantable medical devices.

L6 ANSWER 46 OF 59 EPFULL COPYRIGHT 2005 EPO/FIZ KA on STN

ACCESSION NUMBER: 2005:1584 EPFULL
 ENTRY DATE PATENT: 20050727
 ENTRY DATE PUBLICATION: 20050727
 UPDATE DATE PUBLICAT.: 20050727
 DATA UPDATE DATE: 20050727
 DATA UPDATE WEEK: 200530
 TITLE (ENGLISH): Local vascular delivery of mycophenolic acid in

TITLE (FRENCH): combination with rapamycin to prevent restenosis
 Administration vasculaire et locale de l'acide
 mycophenolique en combinaison avec de rapamycine pour
 prevenir la restenose
 TITLE (GERMAN): Lokale vaskulaere Abgabe von Mycophenolsaeure in
 Kombination mit Rapamycin zur Verhinderung von
 Restenose
 INVENTOR(S): Falotico, Robert, 40 Black Horse Run, Belle Mead, NJ
 08502, US; Parry, Tom Jay, 1452 Bette Lane, Hellertown,
 PA 18055, US; Zhao, Jonathon Z., 12 Briar Hill Court,
 Belle Mead, NJ 08502, US
 PATENT APPLICANT(S): Cordis Corporation, 14201 N.W. 60th Avenue, Miami
 Lakes, Florida 33014, US
 PATENT APPL. NUMBER: 280674
 AGENT: Mercer, Christopher Paul, et al, Carpmaels & Ransford,
 43-45 Bloomsbury Square, London WC1A 2RA, GB
 AGENT NUMBER: 46612
 LANGUAGE OF FILING: English
 LANGUAGE OF PUBL.: English
 LANGUAGE OF PROCEDURE: English
 LANGUAGE OF TITLE: German; English; French
 DOCUMENT TYPE: Patent
 PATENT INFO TYPE: EPA1 Application published with search report
 PATENT INFORMATION:

	NUMBER	KIND	DATE
	EP 1557183	A1	20050727
DESIGNATED STATES:	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT		
	LI LT LU MC NL PL PT RO SE SI SK TR		
EXTENSION STATES:	AL BA HR LV MK YU		
APPLICATION INFO.:	EP 2005-250248	A	20050119
PRIORITY INFO.:	US 2004-761032	A	20040120

ABEN

Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological organism's reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and/or compounds may be utilized to promote healing, including the formation of blood clots. Also, the devices may be modified to promote endothelialization. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until delivered and positioned. In addition, the devices utilized to deliver the implantable medical devices may be modified to reduce the potential for damaging the implantable medical device during deployment. Medical devices include stents, grafts, anastomotic devices, perivascular wraps, sutures and staples. In addition, various polymer combinations may be utilized to control the elution rates of the therapeutic drugs, agents and/or compounds from the implantable medical devices.

(image, 0.1, abstract drawing)

L6 ANSWER 47 OF 59 EPFULL COPYRIGHT 2005 EPO/FIZ KA on STN

ACCESSION NUMBER: 2004:122928 EPFULL
 ENTRY DATE PATENT: 20050706
 ENTRY DATE PUBLICATION: 20050706
 UPDATE DATE PUBLICAT.: 20050706

DATA UPDATE DATE: 20050706
 DATA UPDATE WEEK: 200527
 TITLE (ENGLISH): Histonedacetylase inhibitor eluting medical device
 TITLE (FRENCH): Dispositif medical eluant un inhibiteur d'histone deacetylase
 TITLE (GERMAN): Histone-deacetylaseinhibitor abgebender medizinische Vorrichtung
 INVENTOR(S): Falotico, Robert, 40 Black Horse Run, Belle Mead, NJ 08502, US; Parry, Tom Jay, 1452 Bete Lane, Hellertown, PA 18055, US; Zhao, Jonathan Zhong, 12 Briar Hill Court, Belle Mead, NJ 08502, US
 PATENT APPLICANT(S): Cordis Corporation, 14201 N.W. 60th Avenue, Miami Lakes, Florida 33014, US
 PATENT APPL. NUMBER: 280674
 AGENT: Belcher, Simon James, Urquhart-Dykes & Lord LLP Tower North Central Merrion Way, Leeds LS2 8PA, GB
 AGENT NUMBER: 58312
 LANGUAGE OF FILING: English
 LANGUAGE OF PUBL.: English
 LANGUAGE OF PROCEDURE: English
 LANGUAGE OF TITLE: German; English; French
 DOCUMENT TYPE: Patent
 PATENT INFO TYPE: EPA1 Application published with search report
 PATENT INFORMATION:

	NUMBER	KIND	DATE
	EP 1550472	A1	20050706
DESIGNATED STATES:	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT		
	LI LT LU MC NL PL PT RO SE SI SK TR		
EXTENSION STATES:	AL BA HR LV MK YU		
APPLICATION INFO.:	EP 2004-257842	A	20041216
PRIORITY INFO.:	US 2003-742346	A	20031219

ABEN

A medical device comprising an implantable structure; and a histone deacetylase inhibitor, in therapeutic dosages. The histone deacetylase inhibitor is releasably affixed to the implantable structure for the treatment of restenosis following vascular injury. The device may further comprise an anti-proliferative, in therapeutic dosages, releasably affixed to the implantable structure for the treatment of restenosis following vascular injury. The histone deacetylase inhibitor may comprise trichostatin A. The anti-proliferative may comprise rapamycin.

(image, 0.1, abstract drawing)

L6 ANSWER 48 OF 59 EPFULL COPYRIGHT 2005 EPO/FIZ KA on STN

ACCESSION NUMBER: 2004:116646 EPFULL
 ENTRY DATE PATENT: 20050622
 ENTRY DATE PUBLICATION: 20051006
 UPDATE DATE PUBLICATION: 20051006
 DATA UPDATE DATE: 20051005
 DATA UPDATE WEEK: 200540
 TITLE (ENGLISH): Endovascular graft with differentiable porosity along its length
 TITLE (FRENCH): Prothese endovasculaire a porosite differentiee sur sa longueur
 TITLE (GERMAN): Endovaskulaeres Implantat mit ueber seine Laenge veraenderlicher Poroestaet
 INVENTOR(S): Rush, Scott Lyle, 4744 NW 99 Lane, Coral Springs FL 33076, US
 PATENT APPLICANT(S): Cordis Corporation, 14201 N.W. 60th Avenue Miami Lakes,, Florida 33014, US

PATENT APPL. NUMBER: 280674
 AGENT: Mercer, Christopher Paul, et al, Carpmaels & Ransford,
 43-45 Bloomsbury Square, London WC1A 2RA, GB
 AGENT NUMBER: 46612
 LANGUAGE OF FILING: English
 LANGUAGE OF PUBL.: English
 LANGUAGE OF PROCEDURE: English
 LANGUAGE OF TITLE: German; English; French
 DOCUMENT TYPE: Patent
 PATENT INFO TYPE: EPA3 Separate publication of search report
 PATENT INFORMATION:

	NUMBER	KIND	DATE
	EP 1543798	A3	20051005
DESIGNATED STATES:	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR		
EXTENSION STATES:	AL BA HR LV MK YU		
APPLICATION INFO.:	EP 2004-257864	A	20041216
PRIORITY INFO.:	US 2003-737983	A	20031217

L6 ANSWER 49 OF 59 EPFULL COPYRIGHT 2005 EPO/FIZ KA on STN

ACCESSION NUMBER: 2004:61415 EPFULL
 ENTRY DATE PATENT: 20050209
 ENTRY DATE PUBLICATION: 20050209
 UPDATE DATE PUBLICAT.: 20051026
 DATA UPDATE DATE: 20051026
 DATA UPDATE WEEK: 200543
 TITLE (ENGLISH): A coating for controlled release of a therapeutic agent
 TITLE (FRENCH): Revetement pour la liberation controllee d'un agent
 therapeutique
 TITLE (GERMAN): Schicht fuer kontrollierte Freigabe eines
 therapeutischen Wirkstoffes
 INVENTOR(S): Borges, John, 13988 Lake Lure Ct., Miami Lakes, FL
 33014, US; Carballo, Maritza, 3607 SW 166 Avenue,
 Miramar, FL 33027, US; Narayanan, Pallassana V., 3
 Sweet Briar Court, Belle Mead, NJ 08502, US; Shaw,
 William D., Jr., 761 NW 7th Avenue, Plantation, FL
 33317, US; Widenhouse, Chistopher W., 610 SW 164th
 Avenue, Pembroke Pines, FL 33027, US
 PATENT APPLICANT(S): Cordis Corporation, 14201 N.W. 60th Avenue, Miami
 Lakes, Florida 33014, US

PATENT APPL. NUMBER: 280674
 AGENT: Belcher, Simon James, Urquhart-Dykes & Lord LLP Tower
 North Central Merriion Way, Leeds LS2 8PA, GB
 AGENT NUMBER: 58313
 LANGUAGE OF FILING: English
 LANGUAGE OF PUBL.: English
 LANGUAGE OF PROCEDURE: English
 LANGUAGE OF TITLE: German; English; French
 DOCUMENT TYPE: Patent
 PATENT INFO TYPE: EPA1 Application published with search report
 PATENT INFORMATION:

	NUMBER	KIND	DATE
	EP 1504775	A1	20050209
DESIGNATED STATES:	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR		
APPLICATION INFO.:	EP 2004-254535	A	20040729
PRIORITY INFO.:	US 2003-491646P	P	20030731
	US 2004-883328	A	20040701

ABEN

A composition for coating the surface of an implantable medical device is discussed. The composition comprises: a basecoat matrix, including at least one agent, in therapeutic dosages, incorporated in a first polymeric material, the basecoat matrix being affixed to the surface of the implantable medical device; and a topcoat, including a second polymeric material, affixed to the basecoat matrix for controlling the elution rate of the at least one agent. The at least one agent can also be incorporated in a fluropolymer together with a topcoat including an acrylic polymer. An implantable medical device including the coating is also discussed.

L6 ANSWER 50 OF 59 EPFULL COPYRIGHT 2005 EPO/FIZ KA on STN

ACCESSION NUMBER: 2004:28245 EPFULL
 UPDATE DATE PUBLICAT.: 20050817
 DATA UPDATE DATE: 20050817
 DATA UPDATE WEEK: 200533
 TITLE (ENGLISH): Increased biocompatibility of implantable medical devices
 TITLE (FRENCH): Biocompatibilite amelioree des dispositifs medicaux implantables
 TITLE (GERMAN): Erhoehte Biokompatibilitaet medizinischer Implantate
 INVENTOR(S): Falotico, Robert, 40 Black Horse Run, Belle Mead, NJ 08502, US
 PATENT APPLICANT(S): Cordis Corporation, 14201 N.W. 60th Avenue, Miami Lakes, Florida 33014, US
 PATENT APPL. NUMBER: 280674
 AGENT: Belcher, Simon James, Urquhart-Dykes & Lord LLP Tower North Central Merrion Way, Leeds LS2 8PA, GB
 AGENT NUMBER: 58311
 LANGUAGE OF FILING: English
 LANGUAGE OF PUBL.: English
 LANGUAGE OF PROCEDURE: English
 LANGUAGE OF TITLE: German; English; French
 DOCUMENT TYPE: Patent
 PATENT INFO TYPE: EPA1 Application published with search report
 PATENT INFORMATION:

	NUMBER	KIND	DATE
	EP 1479402	A1	20041124
DESIGNATED STATES:	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR		
APPLICATION INFO.:	EP 2004-252956	A	20040520
PRIORITY INFO.:	US 2003-471943P	P	20030520
	US 2004-848090	A	20040518

ABEN

An implantable intraluminal medical device is described. The medical device comprises a substantially tubular member having open ends, a first diameter for insertion into a lumen of a vein and a second diameter for anchoring in the lumen of a vessel. An agent, in therapeutic dosages, is affixed to the substantially tubular structure for promoting endothelialization of the substantially tubular structure.

(image, 0.1, abstract drawing)

L6 ANSWER 51 OF 59 EPFULL COPYRIGHT 2005 EPO/FIZ KA on STN

ACCESSION NUMBER: 2004:11300 EPFULL
 UPDATE DATE PUBLICAT.: 20050706
 DATA UPDATE DATE: 20050706
 DATA UPDATE WEEK: 200527
 TITLE (ENGLISH): Modified delivery device for coated medical devices
 TITLE (FRENCH): Dispositif d'introduction pour dispositifs medicaux

recouverts
 TITLE (GERMAN): Vorrichtung zum Einbringen beschichteter medizinischer Implantate
 INVENTOR(S): Houghton, Michael J., 1206 Virginia Ave., Newark, DE 19711, US; Majercak, David C., 519 Madison Drive, Stewartsville, NJ 08886, US
 PATENT APPLICANT(S): Cordis Corporation, 14201 N.W. 60th Avenue, Miami Lakes, Florida 33014, US
 PATENT APPL. NUMBER: 280674
 AGENT: Belcher, Simon James, Urquhart-Dykes & Lord LLP Tower North Central Merrion Way, Leeds LS2 8PA, GB
 AGENT NUMBER: 58311
 LANGUAGE OF FILING: English
 LANGUAGE OF PUBL.: English
 LANGUAGE OF PROCEDURE: English
 LANGUAGE OF TITLE: German; English; French
 DOCUMENT TYPE: Patent
 PATENT INFO TYPE: EPA1 Application published with search report
 PATENT INFORMATION:

	NUMBER	KIND	DATE
	EP 1466570	A1	20041013
DESIGNATED STATES:	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR		
APPLICATION INFO.:	EP 2004-251872	A	20040330
PRIORITY INFO.:	US 2003-403195	A	20030331

ABEN

A self-expanding stent delivery system has a substantially tubular shaft (5012) having a proximal end, a distal end, a guidewire lumen (5034) extending between the proximal and distal ends. A stent bed region (5042) is provided proximate the distal end upon which the self-expanding stent is positioned. The stent bed region includes a textured surface (5200) for preventing longitudinal movement of the stent along the shaft. A substantially tubular sheath (5060) defining an interior volume and coaxially positioned over the tubular shaft and the stent.

(image, 0.1, abstract drawing)

L6 ANSWER 52 OF 59 EPFULL COPYRIGHT 2005 EPO/FIZ KA on STN

ACCESSION NUMBER: 2004:3988 EPFULL
 UPDATE DATE PUBLICAT.: 20050518
 DATA UPDATE DATE: 20050518
 DATA UPDATE WEEK:- 200520
 TITLE (ENGLISH): Medical devices comprising rapamycin
 TITLE (FRENCH): Dispositifs medicaux incorporant de la rapamycine
 TITLE (GERMAN): Rapamycin enthaltende medizinische Vorrichtungen
 INVENTOR(S): Roth, Noah M., 416 Magnolia Street, Highland Park, NJ 08904, US; Rush, Scott Lyle, 4744 NW 99 Lane, Coral Springs, FL 33076, US; Scheuble, Theresa, 49 Stephen Place, Rockaway, NJ 07866, US
 PATENT APPLICANT(S): Cordis Corporation, 14201 N.W. 60th Avenue, Miami Lakes Florida 33014, US
 PATENT APPL. NUMBER: 280674
 AGENT: Belcher, Simon James, Urquhart-Dykes & Lord LLP Tower North Central Merrion Way, Leeds LS2 8PA, GB
 AGENT NUMBER: 58312
 LANGUAGE OF FILING: English
 LANGUAGE OF PUBL.: English
 LANGUAGE OF PROCEDURE: English
 LANGUAGE OF TITLE: German; English; French
 DOCUMENT TYPE: Patent

PATENT INFO TYPE: EPA1 Application published with search report
PATENT INFORMATION:

	NUMBER	KIND	DATE
	EP 1449545	A1	20040825
DESIGNATED STATES:	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI		
	LU MC NL PT RO SE SI SK TR		
APPLICATION INFO.:	EP 2004-250847	A	20040218
PRIORITY INFO.:	US 2003-371925	A	20030220

ABEN

A medical device for securing biological tissue to biological tissue and biological tissue to synthetic material comprises a fastening element and a therapeutic dosage of rapamycin releasably affixed to at least a portion of the fastening element for the prevention of neointimal hyperplasia in the biological tissue proximate the fastening element. The fastening element can comprise a staple or a suture.

L6 ANSWER 53 OF 59 EPFULL COPYRIGHT 2005 EPO/FIZ KA on STN

ACCESSION NUMBER: 2004:2082 EPFULL
UPDATE DATE PUBLICAT.: 20050504
DATA UPDATE DATE: 20050504
DATA UPDATE WEEK: 200518
TITLE (ENGLISH): Coated endovascular device
TITLE (FRENCH): Dispositif endovasculaire muni d'un revetement
TITLE (GERMAN): Beschichtete endovaskulaere Vorrichtung
INVENTOR(S): Rush, Scott Lyle, 4744 NW 99 Lane, Coral Springs, FL 33076, US
PATENT APPLICANT(S): Cordis Corporation, 14201 N.W. 60th Avenue, Miami Lakes Florida 33014, US
PATENT APPL. NUMBER: 280674
AGENT: Belcher, Simon James, Urquhart-Dykes & Lord LLP Tower North Central Merrion Way, Leeds LS2 8PA, GB
AGENT NUMBER: 58312
LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
LANGUAGE OF PROCEDURE: English
LANGUAGE OF TITLE: German; English; French
DOCUMENT TYPE: Patent
PATENT INFO TYPE: EPA1 Application published with search report
PATENT INFORMATION:

	NUMBER	KIND	DATE
	EP 1442757	A1	20040804
DESIGNATED STATES:	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI		
	LU MC NL PT RO SE SI SK TR		
APPLICATION INFO.:	EP 2004-250326	A	20040122
PRIORITY INFO.:	US 2003-349776	A	20030123

ABEN

Medical devices, and in particular implantable medical devices, are coated to minimize a biological organism's reaction to the introduction of the medical device to the organism. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological organism's reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and/or compounds may be utilized to promote healing, including the formation of blood clots. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until delivered and positioned.

ACCESSION NUMBER: 2003:98397 EPFULL
 UPDATE DATE PUBLICAT.: 20050216
 DATA UPDATE DATE: 20050216
 DATA UPDATE WEEK: 200507
 TITLE (ENGLISH): Anastomosis devices
 TITLE (FRENCH): Dispositif pour l'anastomose
 TITLE (GERMAN): Vorrichtung zur Gefaessanastomosierung
 INVENTOR(S): Weadock, Kevin, 105 Marten Road, Princeton NJ 08889, US
 PATENT APPLICANT(S): Cordis Corporation, 14201 N.W. 60th Avenue, Miami Lakes Florida 33014, US
 PATENT APPL. NUMBER: 280674
 AGENT: Belcher, Simon James, Urquhart-Dykes & Lord LLP Tower North Central Merrion Way, Leeds LS2 8PA, GB
 AGENT NUMBER: 58312
 LANGUAGE OF FILING: English
 LANGUAGE OF PUBL.: English
 LANGUAGE OF PROCEDURE: English
 LANGUAGE OF TITLE: German; English; French
 DOCUMENT TYPE: Patent
 PATENT INFO TYPE: EPA1 Application published with search report
 PATENT INFORMATION:

	NUMBER	KIND	DATE
	EP 1421909	A1	20040526
DESIGNATED STATES:	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI		
	LU MC NL PT RO SE SI SK TR		
APPLICATION INFO.:	EP 2003-256584	A	20031020
PRIORITY INFO.:	US 2002-274770	A	20021021

ABEN

Apparatus for joining substantially tubular organs in a living organism, comprises an anastomosis device for connecting a graft vessel to a target vessel such that two vessels are in fluid communication. At least one agent in a therapeutic dosage is incorporated into the graft vessel for treatment of reactions by the living organism.

(image, 0.1, abstract drawing)

(image, 0.2, abstract drawing)

ACCESSION NUMBER: 2003:86404 EPFULL
 UPDATE DATE PUBLICAT.: 20050120
 DATA UPDATE DATE: 20050119
 DATA UPDATE WEEK: 200503
 TITLE (ENGLISH): Drug releasing anastomosis devices
 TITLE (FRENCH): Dispositif d'anastomose pour liberer un medicament
 TITLE (GERMAN): Anastomosevorrichtung zum Freisetzen von Arzneimitteln
 INVENTOR(S): Evens, Carl J., 47 Bernard Street, Branchburg, NJ 08876, US; Weadock, Kevin, 105 Marten Road, Princeton, NJ 08889, US
 PATENT APPLICANT(S): Cordis Corporation, 14201 N.W. 60th Avenue, Miami Lakes Florida 33014, US
 PATENT APPL. NUMBER: 280674
 AGENT: Belcher, Simon James, Urquhart-Dykes & Lord LLP Tower North Central Merrion Way, Leeds LS2 8PA, GB
 AGENT NUMBER: 58311
 LANGUAGE OF FILING: English
 LANGUAGE OF PUBL.: English
 LANGUAGE OF PROCEDURE: English

LANGUAGE OF TITLE: German; English; French
DOCUMENT TYPE: Patent
PATENT INFO TYPE: EPAl Application published with search report
PATENT INFORMATION:

	NUMBER	KIND	DATE
	EP 1413256	A1	20040428
DESIGNATED STATES:	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI		
	LU MC NL PT RO SE SI SK TR		
APPLICATION INFO.:	EP 2003-256585	A	20031020
PRIORITY INFO.:	US 2002-274782	A	20021021

ABEN

Apparatus for joining substantially tubular organs in a living organism, comprises a device for connecting a graft vessel to a target vessel such that the two vessels are in fluid communication. The graft vessel has a first end and a second end, and the first end is everted to form a cuff. The apparatus includes at least one agent in therapeutic dosages incorporated into the cuff for the treatment of reactions by the living organism.

(image, 0.1, abstract drawing)

L6 ANSWER 56 OF 59 EPFULL COPYRIGHT 2005 EPO/FIZ KA on STN

ACCESSION NUMBER: 2003:57567 EPFULL
DATA UPDATE DATE: 20041027
DATA UPDATE WEEK: 200444
TITLE (ENGLISH): Coated vascular devices
TITLE (FRENCH): Dispositifs vasculaires presentant un revetement
TITLE (GERMAN): Beschichtete Gefaessvorrichtungen
INVENTOR(S): Bosma, Gjalt, Dr. Siebingasinger 37, 9218 PV Opeinde,
NL; Van Der Meulen, Joost, Groustins 3, 9251 PD Bergum,
NL
PATENT APPLICANT(S): Cordis Corporation, 14201 N.W. 60th Avenue, Miami Lakes
Florida 33014, US
PATENT APPL. NUMBER: 280674
AGENT: Belcher, Simon James, Urquhart-Dykes & Lord LLP Tower
North Central Merrion Way, Leeds LS2 8PA, GB
AGENT NUMBER: 58311
LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
LANGUAGE OF PROCEDURE: English
LANGUAGE OF TITLE: German; English; French
DOCUMENT TYPE: Patent
PATENT INFO TYPE: EPAl Application published with search report
PATENT INFORMATION:

	NUMBER	KIND	DATE
	EP 1386624	A1	20040204
DESIGNATED STATES:	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI		
	LU MC NL PT RO SE SI SK TR		
APPLICATION INFO.:	EP 2003-254747	A	20030729
PRIORITY INFO.:	US 2002-208581	A	20020730

ABEN

Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological organism's reaction to the introduction of the medical device to the

organism. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until delivered and positioned.

L6 ANSWER 57 OF 59 EPFULL COPYRIGHT 2005 EPO/FIZ KA on STN

ACCESSION NUMBER: 2003:28124 EPFULL
UPDATE DATE PUBLICAT.: 20050525
DATA UPDATE DATE: 20050525
DATA UPDATE WEEK: 200521
TITLE (ENGLISH): Coated medical devices for the treatment of vascular disease
TITLE (FRENCH): Implant medical recouvert d'un revetement pour le traitement d'une maladie vasculaire
TITLE (GERMAN): Beschichtetes medizinisches Implantat zur Behandlung von Gefaesserkrankungen
INVENTOR(S): Falotico, Robert, 40 Black Horse Run, Belle Mead, NJ 08502, US; Spaltro, John, 13 Alpaugh Road, Asbury, NJ 08882, US
PATENT APPLICANT(S): Cordis Corporation, 14201 N.W. 60th Avenue, Miami Lakes Florida 33014, US
PATENT APPL. NUMBER: 280674
AGENT: Belcher, Simon James, Urquhart-Dykes & Lord LLP Tower North Central Merrion Way, Leeds LS2 8PA, GB
AGENT NUMBER: 58311
LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
LANGUAGE OF PROCEDURE: English
LANGUAGE OF TITLE: German; English; French
DOCUMENT TYPE: Patent
PATENT INFO TYPE: EPA1 Application published with search report
PATENT INFORMATION:

	NUMBER	KIND	DATE
	EP 1362602	A1	20031119
DESIGNATED STATES:	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR		
APPLICATION INFO.:	EP 2003-252350	A	20030414
PRIORITY INFO.:	US 2002-122978	A	20020415

ABEN

Implantable medical devices are coated to reduce a biological organism's reaction to the introduction of the medical device to the organism. The medical devices are be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. In addition to reducing or substantially eliminating a biological organism's reaction to the introduction of the medical device to the organism, the medical device in combination with one or more therapeutic drugs, agents and/or compounds may be utilized to treat various vascular diseases, for example, restenosis and vulnerable plaque. In the case of vulnerable plaque, one or more drugs, agents or compounds may be utilized to treat the various aspects of vulnerable plaque and these drugs, agents and/or compounds may be released with a given release profile for the most effective treatment. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until delivered and positioned.

(image, 0.1, abstract drawing)

L6 ANSWER 58 OF 59 EPFULL COPYRIGHT 2005 EPO/FIZ KA on STN

ACCESSION NUMBER: 2003:25752 EPFULL

DATA UPDATE DATE: 20040804
 DATA UPDATE WEEK: 200432
 TITLE (ENGLISH): Coated medical devices
 TITLE (FRENCH): Dispositifs medicaux presentant un revetement
 TITLE (GERMAN): Beschichtete medizinische Geraete
 INVENTOR(S): Davila, Luis A., 10362 N.W. 16 Ct., Coral Springs, FL 33071, US; Wilson, David J., 375 River Road, Branchburg, NJ 08876, US
 PATENT APPLICANT(S): Cordis Corporation, 14201 N.W. 60th Avenue, Miami Lakes Florida 33014, US
 PATENT APPL. NUMBER: 280674
 AGENT: Belcher, Simon James, Urquhart-Dykes & Lord LLP Tower North Central Merrion Way, Leeds LS2 8PA, GB
 AGENT NUMBER: 58311
 LANGUAGE OF FILING: English
 LANGUAGE OF PUBL.: English
 LANGUAGE OF PROCEDURE: English
 LANGUAGE OF TITLE: German; English; French
 DOCUMENT TYPE: Patent
 PATENT INFO TYPE: EPA1 Application published with search report
 PATENT INFORMATION:

	NUMBER	KIND	DATE
	EP 1360967	A1	20031112
DESIGNATED STATES:	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR		
APPLICATION INFO.:	EP 2003-252701	A	20030429
PRIORITY INFO.:	US 2002-136569	A	20020430

ABEN

A stent-graft for implantation into a treatment site of a living organism, comprises a scaffold structure for maintaining luminal patency and a graft material secured to at least a portion of the scaffold structure. A biocompatible vehicle is affixed to at least one of the scaffold structure and graft material, and at least one therapeutic agent is incorporated into the biocompatible vehicle for the treatment of a disease condition. The therapeutic drugs, agents or compounds can further reduce a biological organism's reaction to the introduction of the stent-graft to the organism. Various materials and coating techniques can be utilised to maintain the drugs, agents or compounds on the stent-graft device while it is delivered and positioned.

L6 ANSWER 59 OF 59 EPFULL COPYRIGHT 2005 EPO/FIZ KA on STN

ACCESSION NUMBER: 2001:101289 EPFULL
 ENTRY DATE PUBLICATION: 20050817
 UPDATE DATE PUBLICAT.: 20050817
 DATA UPDATE DATE: 20050817
 DATA UPDATE WEEK: 200533
 TITLE (ENGLISH): COATED MEDICAL DEVICES AND STERILIZATION THEREOF
 TITLE (FRENCH): DISPOSITIFS MEDICAUX REVETUS ET LEUR STERILISATION
 TITLE (GERMAN): BESCHICHTETE MEDIZINISCHE GERAETE UND VERFAHREN ZUR STERILISATION
 INVENTOR(S): BODNAR, Stanko, 23 West Oakland Drive, Whitehouse Station, NJ 08889, US; LLANOS, Gerard, H., 1514 Megan Circle, Stewartsville, NJ 08886, US; ROLLER, Mark, B., 9 Quince Place, North Brunswick, NJ 08902, US; SCOPELIANOS, Angelo, 7 John Stevens Road, Whitehouse Station, NJ 08889, US
 PATENT APPLICANT(S): Cordis Corporation, 14201 N.W. 60th Avenue, Miami Lakes, Florida 33014, US
 PATENT APPL. NUMBER: 280674
 AGENT: Belcher, Simon James, Urquhart-Dykes & Lord LLP Tower

AGENT NUMBER: North Central Merrion Way, Leeds LS2 8PA, GB
 58311
 LANGUAGE OF FILING: English
 LANGUAGE OF PUBL.: English
 LANGUAGE OF PROCEDURE: English
 LANGUAGE OF TITLE: German; English; French
 DOCUMENT TYPE: Patent
 PATENT INFO TYPE: EPB1 Granted patent
 PATENT INFORMATION:
 PATENT INFORMATION:

NUMBER	KIND	DATE
NUMBER	KIND	DATE
EP 1322342	B1	20050817

DESIGNATED STATES: WO 2002026271 20020404
 AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT
 SE TR

APPLICATION INFO.: EP 2001-979348 A 20011001
 WO 2001-US30646 A 20011001
 PRIORITY INFO.: US 2000-675882 A 20000929
 US 2001-850482 A 20010507
 US 2001-887464 A 20010622
 US 2001-962292 A 20010925

CITED NON PATENT LIT.: DATABASE WPI Section Ch, Week 200064 Derwent
 Publications Ltd., London, GB; Class A96, AN
 2000-657627 XP002192095 & JP 2000 237289 A (ETHICON
 INC), 5 September 2000 (2000-09-05) -& EP 1 040 840 A
 (ETHICON INC) 4 October 2000 (2000-10-04)

CITED PATENT LIT.: EP 633032 A
 EP 950386 A
 WO 2000027441 A
 WO 9600093 A
 US 5702669 A